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ABSTRACT 
Estrogen is a female sex hormone that has a variety of biologic actions via 
modulation of gene expression through estrogen receptors (ERs). The protective effect 
of estradiol (E2) and estrogen signaling in colon cancer has been demonstrated in 
epidemiological and clinical data as well as animal experiments.  The overall aim of this 
series of studies is to determine the protective mechanism of estrogen signaling activated 
by E2 and phytoestrogens on colitis and colon cancer. 
First, the estrogenic effect of novel phytoestrogens, trigonelline (Trig) and 3,3-
diindolylmethane (DIM) was determined in non-malignant colonocytes (YAMCs). Both 
molecules decreased cell growth of YAMCs, but their mechanisms of action were 
distinct from E2. Trig increased apoptosis by functional ERs without direct binding to 
ERs while DIM altered the expression of target genes of ERs via increased ER 
transcriptional activity. These data suggest that phytoestrogens could activate estrogen 
signaling through unique mechanisms.   
Second, the protective effect of estrogen signaling on colitis and colitis 
associated colon cancer (CAC) was demonstrated in vitro and in vivo. In the in vitro 
study, IL-6 induced cell growth was observed, and E2 and genistein (GEN) treatment 
inhibited IL-6 actions via an increase of apoptosis and modulation of gene expression 
related to estrogen signaling. In the in vivo colitis experiment, chronic inflammation 
damaged the colon, but E2 treatment increased the recovery of the damaged colon via an 
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increase of cell proliferation with modulation of cytokines. However, GEN treatment 
exacerbated the damage on chronic inflammation. In the CAC model, E2 and GEN 
treatment suppressed the formation of aberrant crypt foci (ACF), premalignant lesions. 
These data suggest that E2 protects the colon and colon epithelial cells, and the 
protective mechanism of estrogen signaling differs depending on the type of injury and 
local conditions. 
Lastly, the interaction of estrogen signaling and the p53 pathway was studied 
using intestinal epithelial cell-specific p53 knockout mice (Tp53ΔIEC). The protective 
effect of E2 in Tp53
ΔIEC mice was observed, suggesting that the suppression of ACF by 
estrogen signaling is partially independent of the p53 pathway. 
Overall, estrogen signaling has a protective property against colitis and colon 
cancer but the protective mechanism of estrogen signaling could be changed from 
apoptosis to proliferation depending on the condition of the colon. In addition, each 
phytoestrogen has a distinct and unique way of influencing the colon. These data help 
clarify the role and the mechanism of estrogen signaling on colon cancer. 
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NOMENCLATURE 
ACF Aberrant crypt foci 
AF domain Activation function domain 
AhR Aryl hydrocarbon receptor 
AR Androgen receptor 
AMPs Antimicrobial proteins 
AOM Azoxymethane 
APC Adenomatous polyposis coli 
ATM Ataxia-Telangiectasia mutated 
ATR Ataxia-Telangiectasia and Rad-3-related 
BAX Bcl-2 associated X protein  
Bcl-2 B cell lymphoma 2 
Bcl-6 B cell lymphoma 6 
BrdU 5-Bromo-2'-deoxyuridine 
CAC Colitis-associated colon cancer 
CCND1 Cyclin D1 
CD Crohn’s disease 
COX-2 Cyclooxygenase-2 
CRE Cyclic AMP-response element 
DAB 3,3’-Diaminobenzidine  
DIM 3,3’-Diindolylmethane 
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DMSO Dimethyl sulfoxide 
DNBS 2,4-Dinitrobenzene sulfonic acid 
DSS Dextran sodium sulfate 
E1 Estrone  
E2 Estradiol 
E3 Estriol 
EAE Experimental autoimmune encephalitis 
EGF Epidermal growth factor 
ER Estrogen receptor 
ERE Estrogen-responsive element 
ERK Extracellular signal-regulated kinases 
FAP Familial adenomatous polyposis 
FBS Fetal bovine serum 
FOXP-3 Forkhead box P3 
GEN Genistein 
GI tract Gastrointestinal tract 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
gp130 Glycoprotein 130 
GPR30 G-protein coupled receptor 30 
H&E staining Hematoxylin and eosin staining 
HAT Histone-acetyltransferase 
IBD Inflammatory bowel disease 
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ICI ICI 182,780 
IEC Intestinal epithelial cell 
IFN-γ Interferon-γ 
IGF-1 Insulin-like growth factor-1 
IL-4 Interleukin-4 
IL-6 Interleukin-6 
IL-10 Interleukin-10 
IL-12 Interleukin-12 
IL-13 Interleukin-13 
IL-17 Interleukin-17 
IL-6R IL-6 receptor 
ITS 0.1% insulin, transferrin, and selenious acid 
JAK Janus kinase 
LBD Ligand binding domain 
MAPK Mitogen activated protein kinases 
MCP-1 Monocyte chemotactic protein 1 
Mdm2 Mouse double minute 2 homolog 
MIP1α Macrophage inflammatory protein 1α 
miR-146b microRNA 146b 
mTOR Mammalian target of rapamycin  
NFκB Nuclear factor kappa-light-chain-enhancer of activated B cells 
NO Nitric oxide 
ix 
OVX Ovariectomization 
PFA Paraformaldehyde 
PGE2 Prostaglandin E2 
PI3K Phosphotidylinositol-3 kinase 
PPARγ Peroxisome proliferator-activated receptor γ 
PUFA n-3 Polyunsaturated fatty acids 
PUMA p53 upregulated modulator of apoptosis 
RAG1 Recombination activating gene 1 
RORγt Retinoid-Acid Receptor-related Orphan Receptor γ t 
ROS Reactive oxygen species 
RT Room temperature 
SOCS3 Suppressor of cytokine signaling 3 
SRC Steroid receptor co-activator 
STAT3 Signal transducer and activator of transcription 3 
TDT Terminal deoxynucleotidyl transferase 
TGFβ Transforming growth factor β 
TFH Follicular T helper lymphocytes 
TH1 Type 1 T helper lymphocytes 
TH2 Type 2 T helper lymphocytes 
TH17 Type 17 T helper lymphocytes 
TNBS 2,4,6-Trinitro benzene sulfonic acid  
TNFα Tumor-necrosis factor α 
x 
Tp53Flox/Flox p53 floxed mice 
Tp53ΔIEC Intestinal epithelial cell-specific p53 knockout mice 
TReg Regulatory T cells 
Trig Trigonelline 
TUNEL assay Terminal deoxynucleotidyl transferase-mediated dUTP nick end 
labeling assay 
UC Ulcerative colitis 
YAMC Young adult mouse colonocytes 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Colon cancer statistics  
Colon cancer is the third most common cancer as well as the third most common 
cause of death by cancers in both sexes [1]. Approximately 102,000 cases of colon 
cancer were newly diagnosed and over 500 deaths were estimated due to colon cancer in 
the U.S. in 2013. However, the diagnosis and death rate of colon cancer has 
continuously decreased by approximately 3% during the last 10 years [2]. The 
development of methods for early detection and the clarification of the pathogenetic 
mechanism of colon carcinogenesis are thought to be the main reason for this decline.  
 
1.2 Colon anatomy  
The colon is the final digestive organ in the gastrointestinal tract (GI tract) and its 
length in humans is approximately 1.1-1.9 meters [3]. The primary functions of the 
colon are absorption of salt and water, production of feces, and storage of feces until 
defecation [4].  The GI tract, including the colon, consists of 4 layers: the serosa, the 
muscularis externa, the submucosa and the mucosa [5]. The serosa is the outer layer of 
tissue covering the GI tract and protects the GI tract from friction with surrounding 
tissues. The muscularis externa is the smooth muscle layer of the digestive tube inside 
the serosa, and the submucosa is the connective tissue containing blood and lymph 
vessels. The mucosa is the epithelial luminal layer surrounded by the submucosa, and its 
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surface is highly folded, increasing the surface area for absorption of nutrients. The 
mucosa is divided into 3 layers: the muscular mucosa, the lamina propria and the 
epithelial. The epithelial layer is made up of millions of invaginations, which are called 
the colonic crypts, a functional unit of the colon, and a primary tissue influenced by 
colon carcinogenesis [6, 7].  
 
1.3. Colon cancer progression  
Cancer development is a multistep progression over many years, and colon 
carcinogenesis may require over 10-15 years to progress from normal epithelial tissue to 
invasive cancer [6, 8, 9]. The progression of colon carcinogenesis has been well 
established, and studies have demonstrated that it arises by accumulation of genetic and 
epigenetic modifications. Colon carcinogenesis is separated into 3 stages depending on 
their physiological features: initiation, promotion, and progression [10]. Initiation is the 
first stage in which DNA damage occurs in a single cell due to spontaneous mutation or 
carcinogen exposure. The DNA repair mechanisms existing in the cell may correct the 
error via repair of damaged DNA or removal of cells with DNA damage, resulting in 
prevention of tumors. If cells with DNA damage escape the DNA repair mechanism, 
they will be vulnerable to producing a malignant tumor. The second step of colon 
carcinogenesis is promotion in which initiated cells form polyps. Though polyps are not 
cancerous, 95% of colorectal cancers originate from adenomatous polyps (adenomas) 
[11]. In this stage, increased cell proliferation expands the initiated cell population, 
forming aberrant crypt foci (ACF), which is a pre-polyp structure within preneoplastic 
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lesions [12]. Further mutation of oncogenes or tumor suppressor genes accumulates in 
initiated cells and induces colon cancer progression, the last stage. During progression, 
aberrant cell proliferation due to accumulated genetic mutation and other factors causes 
malignant transformation of cells which develop from adenoma to carcinoma and 
ultimately become invasive to other tissues or organs during progression.  
 
1.4 Risk factors of colon cancer 
Many risk factors are identified that increase colon cancer incidence [13]. Age is 
the primary risk factor for colon cancer. According to colorectal cancer statistics, 
approximately 60% of colon cancer cases and 70% of deaths by colon cancer occur in 
people age 65 and older [2]. Another risk factor is genetic defect. Colorectal cancer 
develops with a series of genetic mutations on some oncogenes and tumor suppressor 
genes [9]. At least four different genetic defects play a pivotal role in the development of 
colorectal cancer: APC, K-RAS, p53 and SMAD4. The adenomatous polyposis coli 
(APC) protein is associated with Wnt/β-catenin signaling. Wnt/β-catenin signaling is 
essential to the development and regeneration of tissues and APC is a negative regulator 
of Wnt/β-catenin signaling via induction of β-catenin. Inactivation of APC causes 
aberrant activation of Wnt/β-catenin signaling, resulting in loss of the ability to control 
cell proliferation. Loss of function of APC protein is one of the primary causes in 
Familial Adenomatous Polyposis (FAP), an inherited condition causing numerous 
adenomatous polyps [9, 14].  K-RAS is an oncogene involved in EGF (Epidermal 
growth factor) signaling which is a growth factor inducing cell proliferation and 
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blocking apoptosis, and K-RAS mutation is found in 50% of colorectal cancer [15]. p53 
mediates DNA repair signaling and apoptosis [16]. 50% of colorectal cancers have a p53 
mutation.  Loss of p53 function in mice results in a variety of cancers and high mortality 
at a relatively early age, due to a central role of p53 in controlling cell fates [17]. The 
human SMAD4 gene is located in the long arm of chromosome 18 and mutation of 
SMAD4 is the most common abnormality found in colon cancer [18, 19]. SMAD4 is a 
central mediator of transforming growth factor β (TGFβ) signaling. Down-regulation of 
SMAD4 is common in a variety of cancers and is associated with poor prognosis in 
colon cancer. A serial genetic mutation of these genes is associated with 
histopathological changes in the colon and promotion of colon carcinogenesis.  
Various environmental factors influence the risk of colon cancer as well [13]. 
The environment includes all the social, economic, and cultural factors composing a 
lifestyle. The most critical factor from the environment is the diet. Diet and nutrients in 
the diet are strongly correlated with cancer incidence including colon cancer [20, 21]. 
Epidemiological data have demonstrated a positive correlation of high consumption of 
red meat and processed meat with the incidence of colorectal cancer [22]. It has been 
reported that a high dose of N-nitroso compounds and a high level of heme in red meat 
and processed meat function as an inducer of DNA damage and oxidative stress in the 
colon. Cooking red meat at high temperatures increases heterocyclic amines which are 
known as probable carcinogens involved in colon cancer [23-26]. Animal fat is also 
thought to be a risk factor for colorectal cancer because animal fats contain high 
amounts of saturated fatty acids [20, 27]. Saturated fatty acids contribute to production 
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of prostaglandin E2 (PGE2), a marker of inflammation; increased inflammatory signaling 
due to elevated PGE2 is negatively correlated with survival of colon cancer patients [28, 
29]. Saturated fats alter gut microbiota composition and disrupt the metabolism of bile 
acid, which may contribute to the possibility of colon carcinogenesis [30, 31]. Obesity, a 
condition characterized by accumulating excess fat in adipose tissue, is also one of the 
risk factors for colon cancer [20, 32, 33]. Adiposity is related to a state of mild chronic 
inflammation caused by an increase of pro-inflammatory mediators such as interleukin-6 
(IL-6), interferon-γ (IFN-γ) and tumor-necrosis factor (TNF) [34]. Obesity also increases 
the level of insulin and insulin-like growth factor-1 (IGF-1), which influence colon 
carcinogenesis through inhibition of apoptosis and induction of epithelial proliferation 
[35]. In contrast, some natural dietary compounds are negatively correlated with colon 
cancer risk [36]. For example, fish oil, which contains n-3 polyunsaturated fatty acids 
(PUFA), can increase apoptosis and decrease DNA adducts in colonocytes. Likewise, 
curcumin, a polyphenolic compound, also prevents colon carcinogenesis via a decrease 
of reactive oxygen species (ROS) and inhibition of inflammation and growth factor 
related signaling [37-40].  
 
1.5 Estrogen and estrogen signaling  
Estrogen is a female sex hormone that plays a pivotal role in the development 
and function of female sex organs [41, 42]. The ovaries are the primary organ that 
produces estrogen, but recent studies have demonstrated that other organs such as 
adipose tissues can also produce estrogen. Estrogen is derived from cholesterol through a 
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series of enzymatic reactions. There are three naturally occurring estrogens: estrone (E1), 
estradiol (E2), and estriol (E3) (Fig. 1.1). Similar to other steroid hormones, estrogen is 
hydrophobic and it can pass freely through cellular membranes and bind to estrogen 
receptors (ERs) in the cytosol of cells. ERs activated by estrogen can act as a 
transcription factor, translocate into the nucleus, and modulate the expression of target 
genes, which have an estrogen-responsive element (ERE) or an alternative DNA 
sequence such as AP-1 that interacts with ERs [43]. Estrogen can also transduce signals 
via binding to the transmembrane G-protein coupled receptor 30 (GPR30) [44]. 
 
 
 
 
Fig. 1.1 Structures of three natural estrogens [41] 
 
 
 
There are two primary forms of estrogen receptors: ERα and ERβ (Fig 1.2) [45, 
46]. Genes for two subtypes of ERs are on chromosomes 6 and 14; their expression is 
tissue-specific but overlapping. ERα is predominantly expressed in the ovary, liver, and 
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breast, while ERβ is highly expressed in the colon and lung [47]. Though both ERs have 
high homology of their domains, they have different functions on target genes and 
biological responses. ERα is essential for ductal growth, while ERβ is associated with 
pro-differentiative and anti-proliferative functions in the mammary gland. In breast 
cancer development, several studies have shown that ERα induces carcinogenesis while 
ERβ protects against malignancy. This difference is partially due to the different 
influence of each ER on the expression of target genes. For example, cyclin D1 (CCND1) 
is a downstream gene of ERs via the AP-1 site, and CCND1 expression is elevated by 
ERα but inhibited by ERβ [48].  
 
 
 
 
Fig. 1.2 Structure and distribution of subtypes of ERs [45, 47] 
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Because of low homology of the ligand binding domain (LBD) between both 
ERs, different binding affinity to estrogenic molecules may be anticipated (Fig. 1.2). 
Low homology in the activation function 2 (AF2) domain of the LBD is especially 
critical, because the AF2 domain is the transactivation domain, which recruits proteins to 
the ER transcription complex [45, 49, 50]. The AF2 domain is exposed by binding 
ligands, and exposed helix 12 in the AF2 domain interacts with other co-activators or co-
repressors forming the ER transcription complex. Therefore, ERα and ERβ may have 
different co-activators due to the difference on their AF2 domains, resulting in different 
influences on gene profiles and cell physiology. A variety of proteins have been 
identified as co- activators of ERs. These co-activator proteins contain α-helical leucine-
rich peptide motifs, known as LXXLL motifs, which interact with the AF2 domain of 
ERs and include RIP140, TRIP-1/SUG-1, TIF1, SRC-1, TIF2/GRIP-1, ACTR/SRC-3, 
and CBP/p300. Binding of these proteins to ERs induces the recruitment of histone-
acetyltransferase (HAT), an enzyme for chromatin decondensation, making DNA more 
accessible to transcription factors, forming a transcription complex. Transcriptional 
activity of ERs thereby increases due to HAT. 
 
1.6 Estrogen signaling on colon cancer 
Clinical and epidemiological data have demonstrated the relationship between 
colon cancer and estrogen signaling [51-54]. Pre-menopausal women have a lower 
incidence of colon cancer compared to men, but the risk of the disease in women 
elevates to a relative risk similar to men after menopause. However, hormone 
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replacement therapy in post-menopausal women reduces the risk for colon cancer. 
Animal studies support the epidemiologic data from humans as well. Cleveland and his 
colleagues demonstrated that disrupted estrogen signaling increased the formation of 
neoplasms in APCmin/+ mice [51].  Data from our laboratory show that E2 treatment 
suppresses aberrant crypt foci (ACF) formation induced by azoxymethane (AOM), a 
colon specific carcinogen [53]. The protective effect of E2 treatment was reduced in ERβ 
knockout mice, and the expression of ERβ was decreased while ERα expression was 
increased during colon carcinogenesis. This indicates that ERβ, the predominant form of 
ER in the gastrointestinal tract, mediates the protective effect of E2 [53, 55, 56].  
 
1.7 Phytoestrogens  
Phytoestrogens are natural compounds having estrogenic properties derived from 
plants (Fig. 1.3) [57]. They can be divided into three subtypes: isoflavones, lignans, and 
coumestans [58]. Soybeans and soy products contain abundant isoflavones, and other 
legumes are also good sources of dietary isoflavones. Because of their similar structure, 
isoflavones have high binding affinity to ERs and can induce ER-mediated 
transcriptional activity. Plant lignans are converted to mammalian lignans by gut 
microflora and the major mammalian lignans are enterolactone and enterodiol. Plant 
ligans are found in flax seeds, dried seaweeds, legumes and other cereals. Due to the 
distinct structure of lignans, they hardly bind to ERs, but they do have estrogenic 
properties. Lignans interrupt E2 binding to ERs and modulate target genes of ERs [59]. 
Coumestans are found in a variety of plants, and some coumestans have estrogenic 
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properties. Coumesterol and 4’- methoxycoumestrol are found in clover.  Coumesterol 
has weak but significant binding affinity to ERs and is capable of interacting with sex 
hormone binding globulin [60]. Coumesterol can inhibit the biosynthesis of estrogens 
via suppression of enzymes such as aromatase. In addition, recent studies have identified 
a new class of estrogenic molecules, which have structures distinct from natural 
estrogens or traditional phytoestrogens [61]. Unlike known phytoestrogens, they do not 
compete with E2 for binding to ERs because of their unique structures [61, 62]. 
 
 
 
 
Fig. 1.3 Structures of estrogens and some phytoestrogens: E2 (natural 
estrogen), diethylstilbestrol (synthetic estrogen), tamoxifen (synthetic antiestrogen), 
genistein (isoflavone),  coumestrol (coumestans), and enterolactone (lignan) [58] 
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1.8 The effect of phytoestrogens on colon cancer  
The effect of phytoestrogens has been well-studied as an alternative for hormone 
replacement therapy [63]. Genistein, coumestrol, and enterolactone have been reported 
to increase cell proliferation of MCF7 breast cancer cells which are estrogen-dependent 
[64-66]. However, phytoestrogens also have anti-estrogenic activity depending on their 
concentration [67]. Genistein suppressed MCF7 cell growth at 100 μM via calpain-
caspase and p38 mediated apoptosis, coumestrol inhibited DNA synthesis of MCF7 and 
enterolactone inhibited E2-stimulated cell proliferation of MCF7 [66-68]. In colon cancer, 
there is a strong epidemiological correlation between consumption of phytoestrogens 
and reduced incidence of colon cancer; intake of fermented soybean or tofu is correlated 
to a lower incidence of colorectal cancer in Asian populations [69-71]. Animal studies 
have demonstrated anti-tumorigenic properties of genistein or other isoflavones in colon 
cancer [72-75]. Genistein suppressed proliferation and induced apoptosis in the small 
and large intestine. Soy isoflavones reduced colon tumor formation against a high-fat 
diet and AOM. A previous study from our laboratory showed that genistein (GEN), a 
phytoestrogen from soybeans, has protective effects on young adult mouse colonocytes 
(YAMC) via apoptosis in vitro [76]. Because ERβ mediates the protective effect of 
estrogen signaling in colon carcinogenesis, most phytoestrogens could prevent colon 
cancer development via their higher binding affinity to ERβ than ERα [77]. However, 
the protective mechanism of estrogen signaling by E2 and phytoestrogens against colon 
cancer development is still unclear.  
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1.9 Immune system and inflammation in the colon 
The immune system is essential to protect our body and to repair the damage 
from an external attack. A variety of immune cells and the molecules they release are 
involved in immune responses. There are two general strategies of the immune system: 
the innate and adaptive immune responses (Fig. 1.4). The inborn ability to recognize 
certain infections is called the innate immune response while the adaptive immune 
response refers to the immune system that has been educated by an initial exposure to an 
infection. The innate immune response functions as the primary defense including 
granulocytes, mast cells, macrophages, dendritic cells, and natural killer cells [78, 79]. 
When components of infectious particles or infected cells are engulfed and presented by 
specialized phagocytes such as macrophages or dendritic cells, cells in the adaptive 
immune response start their role by recognition of the components presented. Adaptive 
immune responses are relatively slow but produce specific immune cells and antibodies 
specializing in the attack. T-lymphocytes and antibodies secreted from B-lymphocytes 
are involved in adaptive immune responses.  
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Fig. 1.4 Innate and adaptive immune system [79] 
 
 
 
The intestinal immune system is complex because the epithelial layer of the GI 
tract separates the host from the outside environment (Fig. 1.5) [80]. Paneth cells and 
goblet cells, among intestinal epithelial cells, release mucus and antimicrobial proteins 
(AMPs), forming the mucus layer that acts as a primary protective barrier. If the 
epithelial barrier function is disrupted, the innate and adaptive immune systems are 
activated. In the colon, the lamina propria in the mucosa layer contains lymphoid vessels 
as well as a variety of innate and adaptive immune cells, and the mesenteric lymph node 
supports the intestinal immune system.  
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Fig. 1.5 Immune system in the colon [81] 
 
 
 
When infected with a virus or bacteria, the body produces many molecules to 
fight and remove the infection using the immune response, accompanied with heat, pain 
and swelling [82, 83]. These symptoms and responses refer to inflammation. 
Inflammation includes the change of damaged cells as well as immune cells. Tissue-
resident macrophages and mast cells recognize the infection or injuries that first produce 
inflammatory molecules such as cytokines and chemokines. These inflammatory 
mediators recruit adaptive immune cells into damaged tissues and induce differentiation 
and activation of effector cells such as CD4+ T lymphocytes. After removal of pathogens, 
tissue recovery and remodeling occurs in the damaged area by activated mesenchymal 
cells. Though inflammation is essential in recovery from infection and tissue injuries, 
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inflammation and inflammatory signaling such as nuclear factor kappa-light-chain-
enhancer of activated B cells (NFκB) is highly correlated with cancer development [84]. 
Epidemiological studies have demonstrated that chronic inflammation due to chronic 
infection or autoimmune disease is associated with cancer, and approximately 20% of 
cancer cases are linked to microbial infection [85].   
 
1.10 Inflammation on colon cancer 
Inflammatory bowel disease (IBD) is a disease resulting from improper innate 
and adaptive immunity in the intestinal epithelial and mucosa [86, 87]. IBD is thought to 
originate from a combined effect of inherited genetic risk and influence of 
environmental factors on the immune system, resulting in aberrant inflammatory 
responses. Several targets have been studied to suppress aberrant inflammation in IBD 
patients including macrophages and T lymphocytes [88]. Clinical analysis of IBD 
encompasses two different types: ulcerative colitis (UC) and Crohn’s disease (CD).  UC 
primarily affects the colon and rectum, while CD arises in any part of the gastrointestinal 
tract from the mouth to the anus. UC is a superficial inflammation associated with type 2 
T helper lymphocytes (TH2), and CD causes a deeper ulceration featuring activated type 
1 T helper lymphocytes (TH1) and type 17 T helper lymphocytes (TH17). To mimic IBD, 
animal models have been developed using chemicals [89-91]. Dextran sodium sulfate 
(DSS) is a toxic molecule that causes damage to the intestinal epithelial cells and 
disrupts the mucosal barrier. The DSS induced colitis model is regarded as a model for 
UC because of similar features to UC, but some research shows that DSS causes simple 
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chemical damage rather than chronic inflammation. 2,4,6-trinitro benzene sulfonic acid 
(TNBS), 2,4-dinitrobenzene sulfonic acid (DNBS), and oxazolone are haptenating 
agents which bind to proteins of the epithelial cell membrane and induce host immune 
responses. TNBS induced colitis has common features of CD, including TH1 activation, 
while colitis induced by oxazolone results in TH2 mediated immune response. 
Both UC and CD are associated with increased risk of colorectal cancer, and 
epidemiological studies have shown that a positive correlation exists between IBD and 
colorectal cancer [92]. Unlike sporadic colon cancers, the mucosa is the major origin of 
tumor formation and p53 mutation might be required in the early stage of colitis-
associated colon cancer (CAC) [93]. Therefore, CAC is an interesting topic in colon 
carcinogenesis. To mimic CAC, chemically induced animal models have been developed: 
animal models with injection of AOM and DSS are commonly used, and AOM-TNBS 
animal models have been reported in some studies for CAC [91, 94].  
 
1.11 CD4+ T cells  
An innate immune response caused by infections induces recruitment of immune 
cells in the adaptive immune response, causing development of effector cells which 
defend against infections [95]. When an innate immune signal is given, naïve CD4+ T 
cells, as one of the adaptive immune cells, differentiate into effector T cells including 
TH1, TH2 and TH17 (Fig. 1.6).  
 
 
 
 17 
 
 
Fig. 1.6 Differentiation of effector CD4+ T cells [95] 
 
 
 
Depending on the inflammatory stimulus, cytokines produced from antigen 
presenting cells are variable, leading to differentiation of specific effector T cells. TH1 
cells are primarily activated when an intracellular infection such as a viral infection 
occurs, and produce interferon-γ (IFN-γ) and interleukin-12 (IL-12) by expressing T-bet. 
TH2 cells are developed during allergic reactions or extracellular stimuli such as 
helminth parasites, and produce IL-4, IL-5 and IL-13 by expression of GATA3. 
Follicular T helper cells (TFH) are a subtype of CD4
+ T cells that regulate antigen-
specific response of B cells, and produce IL-21 by the transcription factor B cell 
lymphoma 6 (Bcl-6). Regulatory T cells (TReg) are thought to suppress immune 
responses for prevention of autoimmune disease and are characterized by production of 
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IL-6 and expression of FOXP-3 (Forkhead box P3) [96]. TH17 cells were identified 
recently and their role is not fully understood [97, 98]. TH17 cells have been found to 
play a critical role in autoimmune diseases including IBD. TH17 cells are associated with 
high levels of IL-6 and featured by production of IL-17 and expression of RORγt 
(Retinoid-Acid Receptor-related Orphan Receptor γ t). 
 
1.12 Role of CD4+ T cells on IBD and colon cancer 
Because TH1/TH17 are associated with CD and TH2 is linked to UC, effector T 
cells are potential targets of IBD [87, 88]. Furthermore, those effector T cells and their 
cytokines are positively correlated to CAC [99]. RAG1 (Recombination activating gene 
1) deficient mice, which have no B cells or T cells, have shown lower incidence of CAC 
in spite of colitis, indicating that adaptive immunity is required for tumor development 
[100]. The role of TH1, TH17 and TH2 has been studied in CAC [94, 101]. TH1 associated 
with IFN-γ has an anti-proliferative property and induces activation of cytotoxic CD8+ T 
cells, resulting in the removal of dysplastic cells. IFN-γ deficient mice showed increased 
tumor formation under a chemically induced CAC model, suggesting that TH1 has a 
protective effect against CAC. In contrast, IL-4 and IL-13 produced from TH2 are 
inducers of cell proliferation and suppress TH1 differentiation.  IL-4 knockout mice have 
shown lower tumor incidence, indicating TH2 has a promoting activity on CAC. TH17 
cells are linked to poor prognosis of patients with colon cancer and loss of their secretory 
cytokine, IL-17, reduced tumor formation in CAC animal models [101]. Furthermore, 
TH1 and TH17 may regulate each other, which have a similar relationship to TH1 and TH2 
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[102]. These data suggested TH17 influences an increase of CAC risk by induction of 
cell proliferation and suppression of TH1. TH17 activation could result in a high 
incidence of colon cancer observed in CD patients in spite of TH1 activation.  
 
1.13 Interleukin-6  
IL-6 is one of the cytokines that is associated with the immune response and 
TH17 activation [99, 103, 104]. It is produced predominantly from monocytes and 
macrophages during inflammation and tissue damage as a mediator of the immune 
response. An increase of the IL-6 receptor or IL-6 itself is observed in colitis, psoriasis 
and other immune diseases, and IL-6 deficient mice are highly susceptible to infection 
by a variety of microorganisms. IL-6 plays a central role in animal models of IBD 
including T- cell transfer in immunodeficient mice or IL-10 deficient mice. The severity 
of colitis was ameliorated in IL-6 deficient mice, and suppression of IL-6 signaling by 
the antibody for IL-6 caused a decrease in epithelial cell proliferation, impairing wound 
healing in colitis [105-107]. These data demonstrate that IL-6, as a central mediator, 
regulates the immune system and increases cell proliferation to restore damaged tissues.  
IL-6 binds to the membrane-bound IL-6 receptor (IL-6R), and IL-6R expression 
is limited to Hepatocytes and some immune cells including macrophages and some 
lymphocytes. The complex of IL-6 and IL-6R interacts with glycoprotein 130 (gp130), 
which is expressed broadly, inducing initiation of signaling. The IL-6 complex activates 
cell signaling molecules including Janus kinase (JAK), signal transducer and activator of 
transcription 3 (STAT3) and mitogen activated protein kinases (MAPK) (Fig. 1.7) [108]. 
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JAK phosphorylated by the IL-6 complex induces phosphorylation of STAT3, causing 
dimerization of STAT3. A dimer of STAT3 acts as a transcription factor, translocates 
into the nucleus, and modulates expression of genes related to cell growth and survival.  
Ras is also activated by IL-6 which initiates a signaling cascade leading to activation of 
MAPK by phosphorylation. In addition, the phosphotidylinositol-3 kinase (PI3K) 
pathway is activated by phospho-JAK, causing phosphorylation of Akt, which induces 
dysregulated cell proliferation and survival. 
 
 
 
 
Fig. 1.7 IL-6 signaling [108]  
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1.14 The role of interleukin-6 on colon cancer 
IL-6 is believed to be a tumor promoting factor in several human cancers 
including lymphoma, melanoma, and breast cancer as well as colorectal cancer [109]. 
IL-6 may suppress apoptosis, increase cell proliferation and induce endothelial migration 
which is a key step of angiogenesis. Antibodies against IL-6 ameliorate cancer related 
anemia and cachexia. Because IL-6 induces differentiation and activation of TH17, TH17 
increased by IL-6 could participate in tumor formation. The tumorigenic effect of IL-6 is 
observed in breast epithelial cells; IL-6 expression induced by monocyte chemotactic 
protein 1 (MCP-1) modified cellular features and led to transformations that made the 
cells tumorigenic [110]. Studies have shown that the expression of IL-6 is increased in 
patients with colon cancer. An increased level of IL-6 is positively correlated with 
cancer stage, metastasis, and poor survival rate of colon cancer patients [111].  Animal 
studies have demonstrated that IL-6 is associated with CAC [112-114]. IL-6 signaling 
was required for the survival of the intestinal epithelial cells, and IL-6 and STAT-3 were 
increased during CAC development. In addition, IL-6 deficiency or suppression of 
gp130 suppressed CAC formation. These data indicate IL-6 signaling plays an important 
role in colon carcinogenesis.  
 
1.15 Estrogen signaling on inflammation and CAC  
Studies have shown that estrogen could modulate the immune system via 
disruption of immune cells and changes in cytokine production [115, 116]. ERs, as a 
major mediator of estrogen signaling, are expressed in most immune cells, and their 
Fig. 4 Abberant 
crypt foci 
within the 
colonic crypts 
of 
ovariectomized 
mice treated 
with AOM and 
TNBS.  A. the 
experimental 
design in vivo for 
generating ACF 
B. total ACF 
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expression is slightly different between pre- and post-menopausal women [117]. ERα is 
highly expressed in monocytes and CD4+ T cells, while ERβ is expressed more than 
ERα in B cells. In contrast, CD8+ T cells expressed both ERs at very low levels. 
Furthermore, E2 changes cytokine levels including NFκB, IL-6, IFN-L, and IL-10. The 
effect of E2 is heterogeneous depending on cell type and estrogen level. For example, E2 
induces IFN-u secretion from T cells while suppressing IFN-r from macrophage and 
dendritic cells.  
The role of estrogen signaling on IL-6 signaling remains unclear. E2 inhibits IL-6 
production during pregnancy but has no influence on IL-6 in post-menopausal women. 
ERs inhibit IL-6 gene expression by disruption of NFκB transactivation [118]. In 
mammary epithelial and breast cancer cells, growth-inhibitory effects of ERβ are 
repressed through activation of MAPK and PI3K, which are targets of IL-6 signaling 
[119]. Studies with a variety of cells demonstrated that estrogen signaling targets several 
IL-6 downstream genes such as STAT3, NFκB and suppressor of cytokine signaling 3 
(SOCS3) [120-122]. These data indicate that there is an interaction between estrogen 
signaling and IL-6 signaling, and the relationship between the two signaling pathways 
could influence inflammation and the immune system.  
It has been reported that estrogen signaling impacts autoimmune diseases and 
inflammation. E2 has protective effects in animal models of arthritis though this result 
was not repeated in clinical studies with rheumatoid arthritis patients. E2 shows a 
suppressive effect against brain inflammation in an experimental autoimmune 
encephalitis (EAE) animal model. This effect is mediated by ERα. In IBD patients, 
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epidemiological data have demonstrated that the symptoms of IBD in female patients 
with CD fluctuate with the estrous cycle, suggesting the level of estrogen plays a critical 
role in CD [123]. However, this effect of estrogen was not observed in UC patients. 
Animal studies with acute colitis showed the protective effect of E2 via suppression of 
cytokines and decrease of macrophages [124, 125]. However, protection by E2 on colitis 
is conflicting with different colitis models, DSS and DNBS. E2 treatment exacerbated 
inflammation in DSS-induced colitis while ameliorating the severity of colitis by DNBS 
through a decrease in the expression of IFN-  and IL-13. These results suggest that the 
protective role of E2 could influence the specific type of colitis, CD. 
Data regarding the influence of estrogen signaling is also conflicting in CAC. 
Saleiro and her colleagues found that loss of ERβ enhanced tumor formation by AOM 
and DSS, suggesting that the protective role of estrogen signaling against CAC is 
mediated by ERβ [126]. Previous data from our laboratory have shown that E2 treatment 
suppressed ACF formation in CAC induced by AOM and DSS via suppression of ERα 
[55]. In contrast, Heijmans’ group has observed that E2 promotes tumor formation via an 
increase of cell proliferation and IL-6 in the AOM/DSS model. Furthermore, they found 
that loss of either ERα or ERβ reduced polyps, suggesting both ERs play a role in 
tumorigenesis of CAC. The differences between these experiments yielding 
contradictory results are ovariectomy (OVX), the time point of E2 administration, and 
the dose of DSS.  
Several studies have reported that phytoestrogens have anti-inflammatory 
properties in IBD and CAC. GEN and soy isoflavones suppressed colitis by DSS or 
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TNBS via modulation of cytokines and cyclooxygenase-2 (COX-2) [127, 128]. In 
addition, DIM inhibited PGE2, nitric oxide (NO), and proinflammatory cytokines, 
resulting in a decrease of DSS-induced colitis and AOM/DSS induced CAC [129].  
 
1.16 The role of p53 in colon cancer  
 p53, a tumor suppressor gene, regulates apoptosis and proliferation in cancer 
cells as well as normal cells. It becomes active in response to a variety of stimuli 
including DNA damage, metabolic stress and oncogene activation [130, 131]. Its 
dysfunction has a powerful impact on cancer development, and mutation or deletion of 
p53 is observed in 60-70% of colorectal cancers [132, 133]. 75% of somatically mutated 
p53 genes are found as missense mutation while nonsense or silent mutations of p53 are 
only found in 25% of somatic mutations in human cancers [134, 135]. Missense 
mutation of p53 replaces a single amino acid followed by stable expression in cancer 
cells not loss of expression. Most p53 mutations occur within exon 5-8, which is the 
DNA binding domain. Mutated p53 interferes with the activity of wild type p53 because 
p53 normally acts as a tetramer and mutated p53 has a dominant negative effect. 
However, it is hard to clarify the role of p53 in colon cancer using p53 knockout mice 
because the effect of p53 mutations induce a variety of cancers with a high death rate at 
an early age [17].  
Recently a genetically modified mouse model has been developed in which p53 
is knocked out in the epithelial cells of the GI tract using the Cre/loxP system [136, 137]. 
Cre is a site-specific DNA recombinase found in bacteriophage P1. Cre recognizes the 
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loxP site, which is a 34 base-pair DNA sequence, and excises DNA between two loxP 
sites, causing loss of a specific gene. To knockout p53 in the intestinal epithelial cells, 
two mouse lines are required: villin-Cre mice and Tp53F/F mice. In villin-Cre mice, Cre 
is expressed in the intestinal epithelial cells only because Cre expression is under the 
control of the villin promoter, which is activated in the intestinal epithelial cells only 
[138]. In Tp53F/F mice, two loxP sites flanked the intron of p53 causing deletion of exon 
2-10 of p53. By mating villin-Cre mice and Tp53F/F mice, a mutant mouse line 
expressing functional p53 in all cells except for the intestinal epithelial cells has been 
developed, which is called Tp53ΔIEC. No physiological changes or infertility issues were 
observed in Tp53ΔIEC mice, but Tp53ΔIEC mice were more susceptible to colon tumor 
formation by AOM.  
The relationship between estrogen signaling and p53 has been studied in various 
types of cancers but the mechanism is not fully understood. Estrogen signaling enhances 
the activity of p53 and regulates the expression of target genes of p53 including the p53 
upregulated modulator of apoptosis (PUMA), B-cell lymphoma 2 (Bcl-2), and Bcl-2 
associated X protein (BAX) [139-143]. Previous studies in our laboratory have shown 
that p53 is a mediator of estrogen signaling and induces apoptosis via regulation of 
mouse double minute 2 homolog (Mdm2) expression and downstream genes [143]. 
Furthermore, E2 suppressed ACF formation was decreased in p53 heterozygous mice 
compared to wild type mice [144]. These data suggest that p53 plays an important role in 
colon carcinogenesis as a signal transducer for estrogen signaling.      
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CHAPTER II  
THE ESTROGENIC EFFECT OF TRIGONELLINE AND 3,3-DIINDOLYMETHANE 
ON CELL GROWTH IN NON-MALIGNANT COLONOCYTES  
 
2.1 Introduction 
Colon cancer is the third most prevalent cancer with over 100,000 newly 
diagnosed cases and is estimated to be the third most common cause of cancer related 
deaths in the United States [1]. Studies show that pre-menopausal women have a 
reduced risk of colon cancer compared to age matched men while post-menopausal 
women have a poorer survival rate than pre-menopausal women [1, 145, 146]. 
Furthermore, data from 18 epidemiological studies demonstrated that hormone 
replacement therapy in post-menopausal women decreased the risk of colon cancer by 
20 % compared to women who never used hormone replacement therapy, indicating a 
relationship between estrogen signaling and colon cancer [54]. The protective role of 
estrogenic action in colon cancer has been supported by animal experiments [51, 53, 147, 
148]. The treatment of estradiol (E2) suppressed the formation of aberrant crypt foci 
(ACF) in a carcinogen-induced mouse model and disruption of estrogen signaling 
enhances colon carcinogenesis [51, 53].  
Data suggest estrogen receptor (ER) β is the primary modulator of estrogen’s 
ability to suppress colon tumor development [53, 126]. Unique ER proteins, ERα and β, 
are produced from two genes and each ER is differently expressed in the body’s tissues, 
including the gastrointestinal tract (GI tract) [149]. ERβ is the predominant form of ER 
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in the GI tract, and lower expression of the protein is correlated to high grade and large 
tumors in the colon [47, 150, 151]. A previous report from our laboratory showed that 
when colon tumors form, there is a novel shift in ER expression where ERβ levels 
decrease accompanied by a large enhancement of ERα protein expression within tumors 
[55]. ERβ specific agonists induced apoptosis and suppressed inflammation in the colon 
epithelium [75, 126]. Furthermore, ERβ suppresses micro-RNAs associated with 
oncogene activation in colon cancer cells [152].  Collectively, these data suggest that the 
activation of estrogen signaling mediated by ERβ has a protective effect against colon 
carcinogenesis.  
While having similar chemical structures as compared to endogenous estrogens, 
a variety of phytoestrogens have been reported including isoflavones and flavones, and 
they are known to have higher binding affinity to ERβ than ERα [77, 153]. Genistein, a 
phytoestrogen isolated from soybeans, has anti-proliferative effects and pro-apoptotic 
effects on the epithelial cells of the small and large intestine in ovariectomized rats [75]. 
Previous data from our laboratory have demonstrated that extracts containing Sorghum 
phenolic compounds suppress growth of young adult mouse colonocytes (YAMCs), and 
this effect was the result of estrogenic action [154]. Studying the chemopreventive 
effects of phytoestrogens on colonocytes could give new alternatives to endogenous 
estrogens to control the risk of colon cancer. Interestingly, recent studies have 
demonstrated molecules found in plants, with distinct structures from endogenous 
estrogens or other commonly studied phytoestrogens, have estrogenic activity [61]. 
Unique to these compounds is that in classic receptor binding assays they do not displace 
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E2 at any concentration, suggesting they do not need to bind in an ER binding pocket to 
elicit an estrogenic response [61, 62]. In this study, we chose two phytoestrogens, 
Trigonelline (Trig) and 3,3-Diindolylmethane (DIM) (Fig. 2.1). Trig and DIM have 
distinctly different chemical structures compared to other phytoestrogens or endogenous 
estrogens, and more importantly their mechanism to modulate estrogen signaling is not 
fully understood. Trig is the niacin-related molecule isolated from coffee beans and it 
has protective properties against diabetes and obesity [155, 156]. A previous report 
demonstrated Trig has an estrogenic effect in estrogen-dependent human breast cancer 
(MCF7) cells though it did not bind to ERs directly via the binding domain [62].  Trig 
can modulate the transcriptional activity of ER inducing ER-mediated target genes. 
However, the role of Trig in a predominant ERβ expressing tissue remains unknown and 
its effect on non-malignant colonocytes has never been studied. DIM is the derivative of 
indol-3-carbinol abundant in Brassica vegetables [157, 158]. Several studies have 
suggested DIM can suppress the growth of prostate cancer and colon cancer, and it 
functions as a modulator of the androgen receptor (AR) and the ER [129, 159-161]. DIM 
has been reported as a new class of ERβ agonist modulating ER binding partners [61].  
Still, the effects of DIM on non-malignant colonocytes remain unclear, especially via 
estrogen signaling. In this study, we examined the effect of Trig and DIM on the cellular 
physiology of non-malignant colonocytes and the role of estrogen signaling on these 
effects.   
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2.2 Materials and methods 
 2.2.1 Reagents 
17β-Estradiol (E2), trigonelline (Trig) and 3,3-diindolylmethane (DIM) were 
purchased from Sigma-Aldrich. ICI 182,780 (ICI) was purchased from Tocris bioscience. 
Reagents were dissolved in dimethyl sulfoxide (DMSO, Sigma-Aldrich).  
 2.2.2 Cells 
Young adult mouse colonocyte (YAMC) bleo/neo cells were provided by Dr. 
Hartmut Land (University of Rochester Medical Center). For regular maintenance, cells 
were cultured in RPMI1640 (Sigma Aldrich) with 10% fetal bovine serum (FBS, 
Hyclone), 0.1% insulin, transferrin, and selenious acid (ITS; BD Biosciences) and 1% 
gentamicin (GIBCO). Cells were maintained in the permissive condition, 33ºC, 5% CO2 
with 5 units interferon-γ (IFN-γ). For the experiments, cells were transferred to media 
containing 10% charcoal-dextran stripped FBS, 0.1% ITS and 1% gentamicin 48 h 
before the experiments. During the experiments, cells were placed at non-permissive 
condition, 39 ºC with 5% CO2.  
2.2.3 Cell growth assay 
Cells were seeded at a concentration of 1.5 × 104 cells/well in 6-well plates 
(Grenier bio-one) and grown at the permissive condition with IFN-γ for 24 h. The cells 
were treated with E2, Trig, or DIM at the appropriate concentrations or 0.1% DMSO as a 
negative control and transferred to non-permissive condition for 96 h. 1 nM E2 was 
treated as a positive control. The concentrations of Trig were 1, 10 or 100 pM, and DIM 
was utilized at 1, 10 or 100 nM. 48 h after the first treatment, media was replaced with 
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fresh media at the same concentration as treatments or 0.1% DMSO. For ICI effect, 1 
µM ICI was co-treated with 1 nM E2, 100 pM Trig or 100 nM DIM. At the end of 96 h 
of treatment, cells were trypsinized and collected for counting. Cell numbers were 
counted using a Beckman Coulter particle counter Z1. 20 µl of cells were diluted in 10 
mL Isotone II diluent (Beckman Coulter) and samples were counted in triplicate. Three 
wells per treatment were used and three replicate experiments were conducted.  
2.2.4 Flow cytometry 
Cells were seeded and grown at the same conditions as the cell growth assay. 
Cells were collected after trypsin treatment and supernatants were removed. After 
washing in ice-cold 1X PBS, cells were fixed with 100% ethanol at -20ºC overnight. 
Fixed cells were stained with propidium iodide staining solution (50 µg/ml propidium 
iodide, 200 µg/ml DNase-free RNase, 4 mM sodium citrate and 0.1% Triton X-100) at 
room temperature (RT) for 30min. 2 × 104 live cells were analyzed using an Accuri C6 
flow cytometer (BD Bioscience) for cell cycle distribution.  
 2.2.5 Caspase-3 activity 
Cells were seeded and grown at the same conditions as the cell growth assay. 
Cells were trypsinized, collected and washed with PBS twice. Caspase-3 activity was 
measured using the manufacture’s protocol for the EnzChek Caspase-3 assay kit #2, Z-
DEVD-R110 substrate (Molecular Probes). Briefly, cells were lysed with 50 µl of 1X 
cell lysis buffer and set on ice for 30 min. Lysed cells were centrifuged at 5000 rpm for 5 
min and 50 µl supernatants were transferred into a 96 well plate (BD Bioscience). 50 µl 
of 2X substrate was added to each well and the plates were incubated at RT for 30 min 
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in the dark. Fluorescence with 496 (excitation)/ 520 (emission) nm was measured at 15 
min intervals.  
2.2.6 Luciferase assay 
Cells were seeded at a concentration of 4 × 104 cells/well in 12 well plates 
(Grenier Bio-One) and grown under permissive conditions with IFN-γ for 24 h.  The 
ERE-TATA luciferase plasmid was provided by Dr. Greene (The University of 
Chicago).  The pRL-TK vector (Promega) was utilized as an internal transfection control. 
Plasmids were transfected into cells using Lipofectamine LTX (Invitrogen) according to 
the manufacturer’s protocol. Briefly, 0.4 µg of ERE-TATA plasmid and 0.2 µg of 
Renilla were co-transfected in each well for 4 h. Cells were treated with 1 nM E2, 100 
pM Trig, 100 nM DIM or 0.1% DMSO for 20 h. After the cells were lysed, luciferase 
assays were performed using a dual-luciferase assay system (Promega) by following the 
recommended protocol. Luminescence was determined using an Infinite M200 Tecan 
plate reader. 
2.2.7 RNA extraction and Real-time PCR  
Cells were seeded at a concentration of 1.4 × 105 cells/dish in 100 mm dishes 
(Corning) and grown at permissive conditions with IFN-γ for 24 h.  The cells were 
treated with 1 nM E2, 100 pM Trig, 100 nM DIM, or 0.1% DMSO for 24 h.  
RNA was isolated using the manufacture’s protocol for TRIzol Reagent 
(Invitrogen). In brief, 1 ml TRIzol reagent was added to trypsinized cells to lyse the cell 
membrane. The addition of 200 µl of chloroform separated the organic layers from lysed 
the cells, and the aqueous phase was transferred to a new tube. RNA was precipitated by 
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adding 500 µl of isopropanol. After washing with 70% ethanol, the pellet was air-dried 
and dissolved in RNase-free water and RNase was inactivated at 55-60ºC. Isolated RNA 
was stored at -70ºC.  
cDNA synthesis was performed with the Transcriptor First Strand cDNA 
synthesis kit (Roche) using the manufacturer’s protocol. In brief, 1 µg of RNA was 
incubated at 65ºC for 10 min with 1 µl oligo dT primer and 2 µl random Hexomer 
primer. After the addition of 4 µl reaction buffer, 0.5 µl RNase inhibitor, 2 µl dNTP and 
0.5 µl reverse trancriptase, thermo cycling was performed: 25ºC for 10 min, 50ºC for 60 
min and 85ºC for 5 min. cDNA was stored at -20ºC.  
Real-Time PCR was performed with FastStart Universal SYBR Green Master 
mix (Roche). The sequence of the PCR primers were as follows: Bcl-2 (Forward: ATC 
TTC TCC TTC CAG CCT GA, Reverse: TCA GTC ATC CAC AGG GCG AT), c-Myc 
(Forward: GCC CAG TGA GGA TAT CTG GA, Reverse: ATC GCA GAT GAA GCT 
CTG G), c-Myb (Forward: TGT CAA CAG AGA ACG AGC TGA, Reverse: CAC 
AGA ACC ACA CTT GCA GC), Mdm2 (Forward: TGT CTG TGT CTA CCG AGG 
GTG, Reverse: TCC AAC GGA CTT TAA CAA CTT CA),  CCND1 (Forward: GCG 
TAC CCT GAC ACC AAT CTC, Reverse: ACT TGA AGT AAG ATA CGG AGG GC) 
and 18S rRNA (Forward: TCA AGA ACG AAA GTC GGA GGT, Reverse: GGA CAT 
CTA AGG GCA TCA CAG). 18S rRNA was utilized as an internal control. RT-PCR 
was run on a Bio-Rad iQ5 thermocycler: 95ºC 10 min, 45 cycles of 15 sec at 95ºC and 
30 sec at 60ºC. 
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2.2.8 Statistical analysis 
The data are expressed throughout as the means ± SEM, which was calculated 
from at least three different experiments. The statistical significance among the test 
groups was determined by one-way ANOVA. A p-value of less than 0.05 was 
considered significant. 
2.3 Results 
 2.3.1 Trig and DIM suppress the cell growth of YAMCs 
The chemical structures of Trig and DIM are shown with E2 in Fig. 2.1. Those 
molecules have a distinct structure from well-characterized phytoestrogens as well as 
estrogen. To investigate the effect of Trig and DIM, we examined the growth of YAMCs 
treated with 1-100 pM Trig or 1-100 µM DIM for 96 h (Fig. 2.2). 1 nM of E2 was 
utilized as a positive control and 0.1% DMSO was used as a negative control. Both Trig 
and DIM suppressed cell growth significantly compared to control by over 20% and the 
effect was stronger than E2. 
Fig. 2.1 The structure of Trigonelline (Trig) and 3,3-Diindolylmethane (DIM) A. 
Trig, B. DIM, and C. 17β-Estradiol (E2) [156, 157] 
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Fig. 2.2 The effect of Trig and DIM on cell growth of YAMCs. Data are 
expressed as percentage of cell numbers of the DMSO control group. Values are means 
(n = 9) ± SEM from triplicate experiments. Bars without a common letter are 
significantly different; p < 0.05. 
 
 
 
2.3.2 Trig and DIM modulate cell cycle progression and apoptosis in YAMCs 
To examine the mechanism of the change in cell growth by Trig and DIM, we 
measured the cell cycle distribution and apoptosis (Fig. 2.3) in YAMCs after treatment 
of 1-100 pM Trig or 1-100 nM DIM with 1 nM E2 as a positive control. E2 was a weak 
modulator of cell cycle distribution through an increase of cells in G2/M phase and a 
decrease of G0/G1 phase cells (Fig. 2.3A). Trig and DIM also had a significant effect on 
cell cycle distribution. Interestingly, Trig and DIM increased the G0/G1 and S phase cells 
not G2/M cells.  
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E2 elevated apoptosis by 40% compared to control and Trig also increased it by 
30% significantly, indicating that Trig may work in part to reduce YAMC number by 
inducing apoptosis (Fig. 2.3B).  DIM had no effect on caspase-3 activity.  
 
 
 
 
Fig. 2.3 The effect of Trig and DIM on cell cycle distribution and apoptosis. 
Cells were treated with 1 nM E2, 1-100 pM Trig or 1-100 nM DIM, and treatments were 
replaced 48 h later. A. Cell cycle distribution was analyzed by Flow cytometry after 
propidium iodide staining. B. Caspase-3 activity was estimated by fluorescence. E2 was 
utilized as a positive control. Data are presented as percentage of vehicle control. Values 
are means (n = 9) ± SEM from triplicate experiments. Bars without a common letter are 
significantly different; p < 0.05. 
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2.3.3 The effect of Trig and DIM on suppression of YAMCs is associated with 
estrogen signaling 
The suppression of YAMC growth by E2 is associated with ER mediated 
signaling. To examine if the effects of Trig and DIM involved estrogen signaling, we co-
treated cells with ICI, an estrogen receptor antagonist (Fig. 2.4A). When we co-treated, 1 
µM of ICI with Trig, DIM and E2, ICI suppressed the effect of Trig and E2 on cell 
growth. However, decrease in cell number by DIM was not influenced by treatment of 
ICI.  
To confirm the influence of Trig and DIM on ER transactivation, the cells were 
transfected with luciferase plasmids containing ERE-TATA (Fig. 2.4B). Renilla 
luciferase was used as an internal control. E2 elevated luciferase activity significantly as 
we expected. Interestingly, DIM increased the reporter activity while Trig did not. It 
shows that DIM has effects on estrogen signaling but its action is not associated with 
classical ligand binding of ERs.  
2.3.4 Trig and DIM regulate the gene expression related to estrogen signaling 
The effects of Trig and DIM on the downstream target genes of estrogen 
signaling and cell growth were examined using RT-PCR (Fig. 2.5). Since Trig and DIM 
showed suppression of cell growth via cell cycle analysis and apoptosis, we chose genes 
related to these cellular processes, cell cycle and apoptosis. Bcl-2 and Mdm2 are linked 
to apoptosis (Fig. 2.5A and B). CCND1, c-Myc and c-Myb are regulators of cell cycle 
progression (Fig. 2.5C, D and E). E2 lowered the expression of all genes but not 
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significantly. Trig decreased c-Myc expression significantly (Fig. 2.5C). In contrast, 
DIM significantly decreased the expression of all genes except for CCND1.  
 
 
 
Fig. 2.4 The effect of Trig and DIM on estrogen signaling. A. 1 µM ICI 182, 
780 was co-treated with Trig or DIM for 96 h to interrupt estrogen signaling on cell 
growth of YAMCs. B. Cells transfected by ERE-luciferase plasmids with renilla 
luciferase plasmids were treated with 100 pM Trig or 100 nM DIM for 20 h. Luciferase 
activity was estimated by luminometer. Renilla luciferase was utilized for internal 
normalization. Data are presented as fold change of vehicle control. Values are means (n 
= 9) ± SEM from triplicate experiments. Bars without a common letter are significantly 
different; p < 0.05. 
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Fig. 2.5 The effect of Trig and DIM on gene expression. Cells were treated with 
1 nM E2, 100 pM Trig or 100 nM DIM for 24 h. A. Bcl-2, B. Mdm2, C. c-Myc, D. 
CCND1, and E. c-Myb were measured by SYBR green expression. The gene expression 
was normalized by 18S. Values are means (n = 9) ± SEM from triplicate experiments. 
Bars without a common letter are significantly different; p < 0.05. 
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2.4 Discussion 
Though epidemiological data have suggested a positive correlation between 
estrogen exposure and reduced colon cancer risk, use of traditional hormone replacement 
therapy has become controversial [54, 162, 163]. As such, understanding the actions of 
plant-derived compounds that mimic estrogenic action in the colon is an attractive 
alternative to suppress the risk of colon cancer [77, 164]. Though some data suggest that 
high concentrations of phytoestrogens suppress colon cancer growth [36], in vitro 
studies with colon cancer cell lines cannot predict the role of these compounds on non-
transformed colonocytes. Therefore, the focus of the presented studies was to elicit the 
action of two novel phytoestrogens on non-malignant colonocytes.   
Trig is a niacin-related molecule commonly found in coffee beans. Little is 
known about the physiological effects of Trig but it has been shown to have anti-diabetic 
properties [155, 156]. A previous study from our laboratory reported that Trig elicits an 
estrogenic response in breast cancer cells, but it does not compete with E2 to bind to the 
binding domain of the ER [62]. In the present study, we evaluated the estrogenic 
potential of Trig in YAMCs. Treatment with the compound suppressed cell growth and 
this effect was inhibited by the co-treatment of ICI, suggesting that activation of the ER 
is necessary for Trig to modulate cell growth. ICI is a well-described antagonist of ERs 
[165, 166]. With a similar structure to E2, ICI binds to the ligand binding pocket of ERs 
and disrupts the dimerization of proteins, resulting in the inactivation of the AF1 and 
AF2 domains. Our observation that ICI attenuated the suppression of cell growth by Trig, 
suggests the possibility that the activation of estrogen signaling by Trig involves 
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enhancement of the dimerization of the ERs or the activation of AF domains. Several 
pathways have been known to activate ERs independent of ligand binding such as 
phosphorylation of the proteins [167]. Furthermore, niacin, the precursor of Trig, is 
known as an activator of EGF receptor resulting in ERK (Extracellular signal-regulated 
kinases) activation [168]. Additional studies are needed to clearly elucidate how Trig 
modifies the activity of ERs.  
Surprisingly, Trig treatment did not significantly induce ER transcriptional 
activity, and except for c-Myc, the expression of ER responsive genes was not 
significantly changed by Trig. Considering our previous data demonstrated that Trig 
elevated ERE activity in MCF7 cells which preferentially express ERα, these data 
suggest that in YAMCs that exclusively express ERβ, the classical ER transcriptional 
mechanism mediated through an ERE is not likely the primary mode of action for Trig 
[47, 62]. Furthermore, Trig induced changes in the cell cycle distribution of YAMCs 
differently from E2 even though it elevated apoptosis in a similar manner as E2. In 
contrast to E2, Trig decreased the expression of c-Myc, which is one of the major 
modulators of the G1/S check point in cell cycle progression and E2 has been shown to 
modulate its expression [169, 170]. Our data suggests that Trig can arrest the cell cycle 
in G1/S phase likely via reduced expression of c-Myc, resulting in suppression of cell 
growth. Furthermore, increased caspase-3 activity by Trig treatment indicates that this 
compound could induce apoptosis, predicting a suppressive effect of colon 
carcinogenesis.  
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ERs modulate cell physiology via genomic pathways and non-genomic pathways 
[45]. In genomic pathways, ERs translocate into the nucleus and alter gene expression. 
This regulation of gene expression is mediated by ERE in the classical pathway. Still, 
ERs change the expression of genes having no EREs via alternative DNA sequences 
including AP-1 sites, Sp1 sites and cyclic AMP-response elements (CREs). Basically, 
ICI induces the degradation of ERs via ubiquitination after ICI binds to the binding 
pocket of ERs [166]. We observed that ICI interrupted the effect of Trig on cell growth 
of YAMCs but found no significant change on the transcriptional activity of ERs by Trig. 
Present data suggest that ERs are essential for the effect of Trig and the classical 
pathway activated by ERs are not involved in the Trig effect because we only used 
traditional EREs to estimate the transcriptional activity. However, we cannot elucidate 
the way to clarify the transcriptional activity of ERs in a non-classical pathway because 
of numerous candidate DNA sequences. Instead, we measured mRNA expression of 
genes known as targets of ERs.   DIM has been shown to be a primary metabolite of 
indol-3-carbinol produced by a condensation reaction when the compound is exposed to 
stomach acid [171]. Indol-3-carbinol is a reported chemopreventive agent in a variety of 
cancers including the liver and colon. Additionally, it appears to play a protective role in 
hormone related cancers as well, including malignancies in the breast and prostate [172]. 
Recent studies have suggested orally administered indol-3-carbinol is converted to DIM, 
which works as an active molecule to suppress tumor formation and modulate cellular 
signaling including via aryl hydrocarbon receptor (AhR), mammalian target of 
rapamycin  (mTOR) and nuclear factor kappa-light-chain-enhancer of activated B cells 
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(NF-κB) related pathways [157]. DIM has been reported as a new class of ERβ selective 
agonists which does not bind to the binding pocket of ERβ but activates ERβ via 
recruiting the steroid receptor co-activator (SRC)-2 [157, 159]. In our study, we found 
that DIM modulates transcriptional activity of ER in YAMCs. Interestingly, DIM 
arrested the cell cycle in the G0/G1 phase but did not induce caspase-3 activity. DIM 
decreased the expression of genes related to the cell cycle and apoptosis except for 
CCND1 which is a cell cycle modulator. All genes measured are known to be modulated 
by ER [48, 62, 143, 173-175]. Bcl-2 is an anti-apoptotic protein that has two EREs in its 
promoter [174]. c-Myb, an oncogene, is associated with a variety of cancers including 
colon cancer and ERα agonists are known to elevate c-Myb expression [175].  Mdm2 is 
a target gene of p53, a tumor suppressor gene as well as a main modulator of the cell 
cycle and apoptosis [130]. Previous studies from our laboratory have demonstrated that 
Mdm2 is decreased by E2 in YAMCs [143]. Gene expression, following exposure to 
DIM, was similar to E2 for these selected targets. Collectively with the ERE 
transcriptional activity assay, these data suggest ER-mediated signaling is similar for 
DIM as that of E2 in non-malignant colonic epithelia. Since Bcl-2, Mdm2, c-Myc, and c-
Myb play an important role in the decision of cell fate, down-regulation of these genes 
suggest that DIM suppresses cell growth by modulation of cell cycle progression. 
Surprisingly, CCND1 expression was not significantly changed by DIM though CCND1 
is known to be modulated by ERs [48]. Unlike what was observed with Trig, ICI did not 
block the effect of DIM on cell growth of YAMCs. These data suggest that the primary 
mode of action for DIM to enhance ER co-activation is more than the classical ER 
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activation via ER dimerization and AF activation. Further studies will explore other 
mechanisms including recruitment of cofactors such as SRC-2 as previously reported 
[159]. 
In summary, we found that Trig and DIM alter cellular physiology of YAMCs 
and both compounds modulate cell cycle progression. Though both molecules have 
estrogenic effects, the way in which they modulate ER signaling seems to be different. 
The effect of Trig on cell growth was blocked by ICI suggesting a functional ER is 
critical to its actions. DIM treatment resulted in ER transcriptional activity and estrogen 
mediated gene expression similar to E2. Collectively, these data suggest that compounds 
that demonstrate estrogenic potential are likely to result in various and unique 
physiological responses and changes in ER signaling in non-malignant colonocytes. We 
have previously shown that the YAMC model serves as a good predictor of 
physiological responsiveness of colonocytes in vivo. Cellular changes observed 
following treatment with Trig and DIM provide compelling evidence that Trig and DIM, 
though novel in structure compared to other phytoestrogens, are likely to prove to be key 
dietary components that may modulate colonocyte physiology and ultimately protect 
these cells against carcinogenesis. 
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CHAPTER III 
ESTRADIOL AND GENISTEIN MODULATE CELL GROWTH OF NON-
MALIGNANT COLONOCYTES INDUCED BY INTERLEUKIN-6. 
3.1 Introduction 
Inflammatory bowel disease (IBD) is an autoimmune disease associated with 
uncontrolled innate and adaptive immunity in the gastrointestinal tract (GI tract), 
resulting in chronic inflammation [176]. Though the cause of IBD is still not understood, 
IBD is thought to result from an aberrant immune response with increased abnormal T 
cell activity [86]. As IBD is related to the increase of colorectal cancer and its critical 
features are shared with colorectal cancer, it is an important risk factor of colitis 
associated colon cancer [92, 177].  Ulcerative colitis (UC) and Crohn’s disease (CD) are 
two primary forms of IBD based on clinical features and histopathology [93, 176]. While 
UC is limited to the mucosa influence on the colon, CD includes whole transmural 
lesions in the entire GI tract. Depending on the type of IBD, the immune system and 
cytokines involved are different [178]. CD is an immune disease mediated by type 1 T 
helper cells (TH1)/type 17 T helper cells (TH17), which are associated with interleukin-6 
(IL-6), interferon γ (IFN-γ) and tumor-necrosis factor α (TNFα). In contrast, type 2 T 
helper cells (TH2) play a main role in UC with IL-13 and transforming growth factor β 
(TGFβ). 
IL-6 is known as a pro-inflammatory cytokine and is secreted in response to 
tissue damage [103]. Blocking IL-6 signaling by anti-IL-6R antibody suppressed 
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inflammation, and T cell transfer from IL-6 deficient mice failed to induce transmural 
colitis. IL-6, produced from macrophages and monocytes, functions as an inducer of the 
activation and differentiation of TH17, which is an IL-17 secretory T cell [179]. IL-6 is 
regarded as a tumor prognostic factor, because IL-6 is associated with increased cell 
proliferation and cell survival, and a higher level of IL-6 is positively correlated with 
advanced stages of colon cancer and higher mortality [104, 109]. The level of IL-6 is 
increased in CD and colitis-associated colon cancer (CAC), and IL-6 signaling plays a 
pivotal role in the survival of intestinal epithelial cells in the CAC model [111, 112]. 
Recently, Rokavec and his colleagues demonstrated that an increased level of IL-6 
induced by monocyte chemotactic protein 1 (MCP-1) excreted from monocytes triggered 
an oncogenic transformation of non-malignant breast epithelial cells. This resulted in 
tumors in immuno-deficient mice [110]. These data suggest that IL-6 could have a 
tumorigenic effect on epithelial cells. 
Pre-menopausal women have a lower incidence of colon cancer as compared to 
age-matched men but post-menopausal women have a poorer survival rate similar to 
men [1, 146]. Studies have shown that hormone replacement therapy (HRT) could 
reduce the incidence of colon cancer in post-menopausal women, suggesting the 
protective effect of estrogen signaling on colon cancer [52, 54]. Previous data from our 
laboratory showed that estradiol (E2) suppressed the incidence of colon cancer induced 
by azoxymethane (AOM) and increased apoptotic molecules through the p53 pathway, 
demonstrating that estrogenic molecules could prevent colon carcinogenesis [53, 143]. 
Epidemiological and animal studies have demonstrated that estrogen ameliorated 
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inflammation [123, 124, 128, 180]. The symptoms of CD in pre-menopausal women 
worsened during menses, when E2 concentrations are at their lowest. E2 modulated the 
infiltration of immune cells and altered cytokine production in chemically induced colitis 
model. Recent data from our laboratory have shown that E2 protects the colon epithelium 
from acute inflammation induced by 2, 4, 6-trinitro benzene sulfonic acid (TNBS) by a 
decrease of pro-inflammatory cytokines including IL-6 [125]. These data suggest that 
estrogen signaling could play a protective role in CAC as well. 
The aim of our study is to examine how IL-6 influences non-malignant 
colonocytes, whether estrogen signaling modulates the change induced by IL-6, and 
what the potential mechanism of modulation by estrogen signaling is on the protection 
for the physiology of colonocytes. Though it has been reported that the estrogen 
receptors could modulate IL-6 gene expression in HeLa cells by inhibition of nuclear 
factor kappa B (NFκB) transactivation, the interaction between IL-6 and estrogen 
signaling remains unclear [118]. In this study, we examined physiological changes of 
young adult mouse colonocytes (YAMCs) induced by IL-6. We also estimated that the 
influence of estrogen signaling induced by E2 or genistein (GEN), a phytoestrogen from 
soybeans, on IL-6 effect to clarify the relationship between the IL-6 pathway and 
estrogen signaling. GEN is a known modulator of inflammation and an enhancer of 
homeostasis in intestinal epithelial cells [75, 181, 182]. The present data will give 
insights the role of IL-6 in the development of CAC and whether estrogen signaling 
could suppress CAC. 
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3.2 Materials and methods 
3.2.1 Reagents 
β-Estradiol (E2) and genistein (GEN) were purchased from Sigma Aldrich, and 
recombinant mouse IL-6 was obtained from Millipore. E2 and GEN were dissolved in 
dimethyl sulfoxide (DMSO, Sigma-Aldrich), and IL-6 was dissolved in ultrapure water.  
3.2.2 Cell culture 
Young adult mouse colonocyte (YAMC) bleo/neo cells and mp53/neo cells were 
provided by Dr. Hartmut Land (University of Rochester Medical Center). For general 
maintenance, cells were cultured in the permissive condition, 33ºC, in RPMI1640 media 
(Sigma Aldrich) with 10% fetal bovine serum (FBS, Hyclone), 1% gentamicin (GIBCO) 
and ITS (0.1% insulin, transferrin, and selenious acid; BD Biosciences) as well as 5 units 
IFN-γ. For experiments, cells were grown in RPMI1640 with 10% charcoal-dextran 
stripped FBS 48 h before the experiments. During the experiments, cells were grown 
without IFN-γ at the non-permissive condition, 39 ºC.  
3.2.3 Cell growth assay 
Cells were seeded at a concentration of 5 × 104 cells/well in 6-well plates 
(Grenier bio-one) and grown in the non-permissive condition for 24 h. The cells were 
treated with 1 nM E2, 1 and 10 µM GEN with or without 15 ng/ml of IL-6 for 72 h. 0.1% 
DMSO was utilized as a control. After 72 h of treatment, cells were trypsinized and 
collected for counting. Cell numbers were counted using a Cellometer Auto 1000 
(Nexcelom Bioscience) according to the manufacturer’s protocol. 20 µl of cells were 
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loaded in the cell counting chamber, and each sample was counted twice. Three wells 
per treatment per experiment were used, and three replicate experiments were conducted. 
3.2.4 Flow cytometry 
Cells were seeded and grown with the same doses of reagents as the cell growth 
assay.  After 72 h, cells were collected by trypsin treatment. Cells were washed with ice-
cold 1X PBS and fixed with 100% ethanol in a -20ºC freezer overnight. Fixed cells were 
incubated with propidium iodide staining solution (50 µg/ml propidium iodide, 200 
µg/ml DNase-free RNase, 4 mM sodium citrate and 0.1% of Triton X-100) at RT for 30 
minutes. Cell cycle distribution was evaluated by Accuri C6 flow cytometer (BD 
Bioscience). 
3.2.5 Caspase-3 activity 
Cells were seeded and treated with the same conditions as the cell growth assay. 
Cells were collected with trypsin and washed with PBS twice. Cells were prepared and 
caspase-3 activity was estimated using the manufacture’s protocol for the EnzChek 
Caspase-3 assay kit #2, Z-DEVD-R110 substrate (Molecular Probes). Briefly, cells were 
lysed with 50 µl of 1X Cell Lysis buffer and incubated on ice for 30 min. Lysed cells 
were centrifuged at 5000 rpm for 5 min and 50 μl supernatants were transferred into a 96 
well black flat bottom plate (BD Bioscience). After adding 50 µl of 2X substrate in each 
well, the plates were incubated at RT for 30 min in the dark. Fluorescence with 496 
(excitation)/ 520 (emission) nm was measured at 15 min intervals using a TECAN 
infinite M200 plate reader. 
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3.2.6 RNA extraction and real-time PCR  
Cells were seeded at a concentration of 4.5 × 105 cells/dish in 100 mm dishes 
(Corning) and grown at the non-permissive condition for 24 h.  The cells were treated 
with 1 nM E2, 1 and 10 µM Genistein with or without 15 ng/ml IL-6 for 72 h. 0.1% 
DMSO was utilized as a control. 
RNA extraction was performed according to the manufacture’s protocol of 
Direct-zol™ RNA MiniPrep (Zymo Research) with TRIzol Reagent (Invitrogen). In 
brief, trypsinized cells were collected and 1 ml TRIzol reagent was added to lyse the cell 
membrane. 1 ml of 100% ethanol was added and samples were mixed by vortexing. 
RNA was isolated using a Zymo-Spin column and eluted in 30 µl of RNase-free water. 
Isolated RNA was stored in a -70ºC freezer. The concentration of RNA in each sample 
was determined using a Nanodrop 2000 (Thermo Fisher Scientific). 
cDNA was synthesized using the manufacturer’s protocol for the Transcriptor 
First Strand cDNA synthesis kit (Roche). In brief, 1 µg of RNA was mixed with 1 µl 
oligo dT primer and 2 µl random hexomer primer and incubated at 65ºC for 10 min. 4 µl 
reaction buffer, 0.5 µl RNase inhibitor, 2 µl dNTP and 0.5 µl reverse trancriptase were 
added to the RNA mixture, incubated, and thermo cycling was conducted at 25ºC for 10 
min, 50ºC for 60 min and 85ºC for 5 min. Synthesized cDNA was stored in a -20ºC 
freezer. 
Real-Time PCR was performed using FastStart Universal SYBR Green Master 
mix (Roche). The sequence of the PCR primers were as follows: ERα (Forward: GAC 
CAG ATG GTC AGT GCC TT and Reverse: ACT CGA GAA GGT GGA CCT GA), 
50 
ERβ (Forward: CAG TAA CAA GGG CAT GGA AC and Reverse: GTA CAT GTC 
CCA CTT CTG AC), CCND1 (Forward: GCG TAC CCT GAC ACC AAT CTC, 
Reverse: ACT TGA AGT AAG ATA CGG AGG GC), PCNA (Forward: TTG CAC 
GTA TAT GCC GAG ACC, Reverse: GGT GAA CAG GCT CAT TCA TCT CT), IL-6 
(Forward: CTG CAA GAG ACT TCC ATC CAG, Reverse: AGT GGT ATA GAC 
AGG TCT GTT GG), and 18S as an internal control (Forward: TCA AGA ACG AAA 
GTC GGA GGT, Reverse: GGA CAT CTA AGG GCA TCA CAG). Real-Time PCR 
was run on a LightCycler®  480 II (Roche): 10 minutes at 95ºC, 45 cycles of 15 seconds 
at 95ºC and 30 seconds at 60ºC. 
3.2.7 Western blot 
Cells were seeded and grown in the same condition as the cell growth assay.  
Cells were harvested and lysed in 1X RIPA buffer with 1 mM PMSF (Cell Signaling 
Technology) for 15 min on ice. After two cycles of freezing and thawing, lysed cells 
were centrifuged at 14,000 rpm for 15 min and the supernatants were transferred into a 
new e-tube. The concentration of proteins was determined using the DC Protein Assay 
(Bio-Rad). Proteins were separated on a 10% Tris-glycine gel (Lonza) and transferred to 
a PVDF membrane (Immobilon-P Membrane; Millipore). Primary antibodies for STAT3 
(Santa Cruz Biotechnology), phospho-STAT3 (Tyr705; Cell Signaling Technology) and 
β-actin (Sigma Aldrich) were utilized at a 1:1000 dilution. After incubation at 4ºC 
overnight with primary antibodies, the blots were incubated with goat anti-rabbit or goat 
anti-mouse secondary antibodies (Enzo lifescience) at a 1:2000 dilution. The blot was 
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visualized using the Immobilon Western Chemiluminescent Horseradish Peroxidase 
(HRP) Substrate Kit (Millipore). 
3.2.8 Statistical analysis 
The data are expressed throughout as means ± SEM, which was calculated from 
at least three different experiments. The statistical significance among the test groups 
was determined by two-way ANOVA using Graphpad. A p-value of less than 0.05 was 
considered significant. 
3.3 Results 
3.3.1 E2 and GEN suppressed cell growth induced by IL-6 
To investigate the effect of IL-6 on YAMCs, we examined the growth of 
YAMCs treated with IL-6 for 72 h (Fig. 3.1A). Though cells were incubated at the non-
permissive condition, IL-6 increased cell growth of YAMCs by 60% (p < 0.0001). Co-
treatment of E2 and IL-6 elevated cell growth by 34% compared to control without IL-6 
(p < 0.0001). The cell numbers by co-treatment of E2 and IL-6 were 20% less than IL-6 
treatment alone (p = 0.0006). Because E2 suppressed cell growth by 20% compared to 
control without IL-6 (p = 0.05), the inhibition rate of cell growth by E2 was still the same 
whether IL-6 was co-treated or not. Though 1 µM of GEN had no influence on cell 
growth, 10 µM of GEN treatment had a suppressive effect on cell growth by 20%, 
similar to E2 with or without IL-6 (p < 0.0001). In contrast, E2 and GEN did not change 
the cell growth of YAMC mp53/neo cells (Fig. 3.1B), which suggests that the apoptotic 
pathway is critical when estrogen signaling modulates cell growth. Furthermore, IL-6 
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did not influence cell growth of YAMC mp53/neo cells, indicating induction of cell 
growth by IL-6 could involve loss of apoptosis.   
 
 
 
 
Fig. 3.1 The effect of IL-6, E2 and GEN on the growth of YAMCs. Cells were 
treated with 1 nM E2, 1 and 10 μM GEN, with or without 15 ng/ml IL-6 for 72 h at 39ºC. 
A. Bleo/Neo. B. mp53/neo. Values are means (n = 9) ± SEM from triplicate experiments. 
Bars without a common letter are significantly different; p < 0.05. 
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3.3.2 E2 and GEN reversed caspase-3 activity decreased by IL-6  
To examine how IL-6 induces cell growth of YAMCs, we estimated apoptosis 
and cell cycle distribution (Fig. 3.2). IL-6 has been reported as an anti-apoptotic 
molecule for T lymphocytes by activation of STAT3, and IL-6 impacts the survival of 
the intestinal epithelial cells in the CAC model [112, 183]. IL-6 reduced caspase-3 
activity (p < 0.0001), suggesting a decrease of apoptosis in YAMCs (Fig. 3.2A). Similar 
to previous data from our laboratory, E2 and GEN elevated apoptosis in YAMCs (p < 
0.0001) [143]. However, the effect of E2 was weak under IL-6 treatment while 10 µM 
GEN recovered apoptotic activity reduced by IL-6 (p = 0.02). Cell cycle distribution was 
analyzed by flow cytometry and IL-6, E2 and GEN did not change cell distribution at all 
(Fig. 3.2B).  
3.3.3 E2 reduced PCNA and CCND1 expression elevated by IL-6 treatment  
IL-6 signaling and estrogen signaling ultimately modulate transcription of genes 
because ERs and all IL-6 targets function as transcription factors [43, 108]. To 
investigate how IL-6 modulates apoptosis, we examined Real-Time PCR for analysis of 
gene expression (Fig. 3.3). IL-6 increased ERα expression in YAMCs (p=0.04), though 
there is no evidence suggesting that IL-6 signaling could change the expression of ERs 
(Fig. 3.3A). 1 nM E2, 1 and 10 µM GEN treatments suppressed the increase of ERα 
expression by IL-6 (p = 0.04, p = 0.07 and p = 0.02). Though ERβ expression was 
slightly increased by IL-6, IL-6 suppressed the ratio of ERβ to ERα (Fig. 3.3B and C, p 
< 0.0001). Because E2 and GEN did not reduce ERβ expression increased by IL-6, E2 
and GEN did not diminish the effect of IL-6 on the ratio of ERβ to ERα. CCND1 
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expression was increased by IL-6 treatment but it was not significant (Fig. 3.3D). Instead, 
PCNA expression was elevated by IL-6 significantly (Fig. 3.3E, p = 0.002). E2 and GEN 
decreased neither CCND1 nor PCNA expression elevated by IL-6. These data suggest 
that IL-6 treatment induces cell proliferation because CCND1 is related to cell cycle 
progression and PCNA is a marker for cell proliferation. Interestingly, IL-6 expression 
was reduced by IL-6 treatment (Fig. 3.3F, p < 0.0001). When IL-6 was not applied, 10 
μM GEN suppressed IL-6 mRNA (p = 0.01). Under IL-6, E2 and GEN reduced IL-6 
expression slightly more than IL-6 treatment alone but the effect was not significant. 
3.3.4 E2 and GEN have no influence on phosphorylation of STAT3 induced by 
IL-6 signaling  
IL-6 signaling transduces its signals through signal transducer and activator of 
transcription 3 (STAT3), phosphotidylinositol-3 kinase (PI3K) and Ras/mitogen 
activated protein kinases (MAPK) [108]. To clarify the mechanism of the effect of E2 
and GEN, the change of the STAT3 protein was examined by Western blot. IL-6 
treatment increased phosphorylation of STAT3 significantly (Fig 3.4). However, E2 and 
GEN did not alter phospho-STAT3 elevated by IL-6. These data indicate that IL-6 
signaling is activated in YAMCs, causing signal transduction via phospho-STAT3. 
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 Fig. 3.2 Apoptosis and Cell cycle distribution in YAMCs treated with IL-6, 
E2 and GEN. Cells were treated with 1 nM E2, 1 and 10 μM GEN, with or without 15 
ng/ml IL-6 for 72 h at 39ºC. A. Caspase-3 activity. Data are expressed as increased 
fluorescence measured when compared with the control based on cell growth rate. B. 
Cell cycle distribution was analyzed by flow cytometry. Data are presented as 
percentage of vehicle control. Values are means (n = 9) ±SEM from triplicate 
experiments. Bars without a common letter are significantly different; p < 0.05. 
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Fig. 3.3 Changes of gene expression in YAMCs treated with IL-6, E2 and 
GEN. Cells were treated with 1 nM E2, 1 and 10 μM GEN, with or without 15 ng/ml IL-
6 for 72 h at 39ºC. A. ERα, B. ERβ, C. Ratio of ERβ to ERα, D. CCND1, E. PCNA and 
F. IL-6. Values are presented as ratio of the expression compared to vehicle control. 
Values are means (n = 9) ±SEM from triplicate experiments. Bars without a common 
letter are significantly different; p < 0.05. 
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Fig. 3.4 Change of phospho-STAT3 and STAT3 in YAMC cells treated with 
IL-6, E2 and GEN. Cells were treated with 1 nM E2, 1 and 10 μM GEN, with or without 
15 ng/ml IL-6 for 72 h at 39ºC. 
3.4 Discussion 
Studies have been conducted to elucidate the role of estrogen and estrogen 
signaling on the physiology of cells in non-reproductive tissues. Especially in cancers, 
their role is changed depending on timing, tissues and the major form of ERs expressed 
[46, 47]. Previous articles have demonstrated that E2 has a protective activity in colon 
carcinogenesis and acute inflammation through induction of the p53 pathway and this 
protection is mediated by ERβ, the predominant ER in the colon epithelial [53, 56, 143]. 
Still, to our knowledge, the role of estrogen signaling against inflammation in the 
colonocytes has not been fully elucidated. 
 Though IBD is a known risk factor for colon cancer, its mechanism for cancer 
progression is different from sporadic cancer [92, 93].  Because IBD is a chronic 
inflammation, a variety of cytokines are involved. IL-6 is one of the cytokines related to 
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the immune responses and IBD. IL-6 binds to the IL-6 receptor which activates 
downstream signaling such as STAT3, resulting in gene regulation [108]. IL-6 signaling 
induces cell proliferation as well as the differentiation of TH17 cells. In the present study, 
we demonstrated that YAMCs, non-malignant colonocytes, responded to IL-6 treatment; 
IL-6 increased cell proliferation, modulated gene expression, suppressed apoptosis, as 
well as induced phosphorylation of STAT3. These data suggest that the coloncytes may 
have IL-6 receptors and IL-6 treatment induced IL-6 signaling in YAMCs. Because 
STAT3 is a transcription factor that controls genes related to cell survival and 
proliferation, increased phospho-STAT3 due to IL-6 signaling could be a mediator that 
changes downstream target genes such as CCND1 and PCNA. As a result, activated IL-6 
signaling reduced apoptosis and increased cell proliferation in YAMCs. These data 
suggest that IL-6 signaling could influence the physiology of colonocytes and the 
inflammatory response in the colon epithelial could result in increased cell proliferation. 
Interestingly, IL-6 gene expression was decreased by IL-6 treatment though IL-6 
is known as a target of phospho-STAT3 [184]. The present data suggest that non-
cancerous cells could have the ability to diminish IL-6 signaling, because aberrant IL-6 
signaling is one of the markers for cancer. A recent study demonstrated a negative 
feedback loop of IL-6 in the breast mediated by microRNA 146b (miR-146b) [185]. 
miR-146b is highly expressed in the breast epithelial, while its expression is low in 
breast tumors due to methylation of its promoter. STAT3 induced miR-146b, 
suppressing IL-6 production via inhibition of NFκB. The present data showing that IL-6 
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treatment lowered the expression of the IL-6 gene could be due to the activation of a 
negative feedback loop for IL-6 signaling in non-malignant cells. 
Recent studies demonstrated that estrogen signaling is also related to 
carcinogenesis. Estrogen signaling may accelerate or exacerbate cancers in tissues 
related to reproduction, such as the breast, because ERα is the predominant form of ER 
in most of these tissues. There are two primary forms of ERs, ERα and ERβ. While ERα 
is known to induce cell proliferation for the development of tissues such as the breast, 
ERβ is negatively correlated to cell growth and cancer development. Previous data from 
our laboratory demonstrated that E2 has a protective effect against colon carcinogenesis 
because ERβ is the major form of ER in the colon, and the novel shift from ERβ to ERα 
occurs during the development of colon cancer. In the present study, IL-6 treatment 
increased ERα expression and decreased the ratio of ERβ to ERα, indicating that IL-6 
signaling could be involved in the physiological changes of colonocytes progressing to 
malignancy. 
Previous data from our laboratory showed that E2 suppressed cell growth and 
increased apoptosis in YAMCs. E2 still has the ability to modulate cell growth and 
apoptosis under IL-6 treatment in the present study. Furthermore, E2 reversed increased 
ERα expression by IL-6. There are two possible explanations for the effect of E2. One is 
that E2 inhibited IL-6 signaling through an interaction of signaling molecules in 
downstream pathways of IL-6 such as STAT3. The other is that E2 enhanced the other 
pathways related to tumor suppression. E2 treatment enhanced the decrease of IL-6 
expression, which could result in a decrease in IL-6 signaling. The data that phospho-
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STAT3 was not changed by E2 suggests that estrogen signaling could modulate other 
pathways. Still, further study is required to understand how E2 treatment interrupts IL-6 
induced cell proliferation. IL-6 induces three major signaling pathways: STAT3, PI3K 
and Ras [108]. Though present data suggests that E2 has no influence on phosphorylation 
of STAT3, two other downstream targets of IL-6, PI3K or Ras, could be a target of 
estrogen signaling. The interaction between ERβ and activation of MAPK and PI3K has 
been reported in breast epithelial and cancer cells [119]. In addition, the data showed 
that E2 decreased cell growth by 20% with or without IL-6 and the effect of IL-6 was 
diminished on YAMCs with mutated p53. Because increased apoptosis by E2 is 
mediated by p53 and p53 suppressed IL-6 expression, these data suggest that p53 could 
be a mediator of estrogen signaling and the IL-6 pathway on cell growth of YAMCs 
[143, 186, 187]. 
GEN is a phytoestrogen that has a higher biding affinity to ERβ than ERα [77]. 
As one of the flavonoids, it has been reported that GEN has an anti-tumorigenic and 
anti-inflammatory capacity in vitro and in vivo [64, 68, 75, 128]. Previous data with 
YAMCs and mice have shown that GEN suppressed cell growth and increased apoptosis 
similar to E2 [76]. In this study, 10 μM of GEN had a similar effect on cell growth and 
apoptosis as E2. 10 μM of GEN also inhibited the expression of IL-6 under IL-6 was not 
treated. GEN had no influence on the level of phospho-STAT3. Taken together, these 
data suggest that the suppressive effect of GEN against IL-6 could be more than an 
estrogenic effect. Numerous biological properties of GEN have been reported besides 
the estrogenic effect: a protein kinase inhibitor, a topoisomerase II inhibitor, suppression 
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of phosphatidylinositol turn over, an antioxidant, an agonist for peroxisome proliferator-
activated receptor γ (PPARγ), as well as an anti-inflammatory agent [144, 188, 189]. 
Therefore, other pathways influenced by GEN could modulate IL-6 induced cell 
proliferation with estrogen signaling.  
In conclusion, IL-6 signaling could be activated in non-malignant colonocytes 
via phosphorylation of STAT3. IL-6 signaling causes an increase in cell proliferation 
and a decrease of apoptosis via a change of gene expression. Estrogen signaling by E2 
treatment suppressed cell proliferation against IL-6 signaling, but the effect was not 
mediated by STAT3. GEN has a similar inhibitory activity on increased cell proliferation 
by IL-6, but the influence by GEN may not include estrogen signaling, though GEN is a 
representative phytoestrogen. These findings together suggest that IL-6 signaling could 
play an important role in colon carcinogenesis, and estrogen signaling partially disrupts 
IL-6 signaling, resulting in the prevention of colon cancer.  
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CHAPTER IV 
DUAL EFFECTS OF ESTRADIOL SUPPRESS COLITIS AND 
COLITIS ASSOCIATED COLON CANCER. 
4.1 Introduction 
Chronic inflammation is positively correlated with a variety of cancers including 
colon cancer [84]. Inflammatory bowel disease (IBD) is prevalent in the U.S., with over 
1.4 million people are suffering from IBD [190]. This disease refers to a condition with 
chronic or recurring inflammation and/or immune response in the gastrointestinal tract 
(GI tract) [86, 176, 178]. The two most common forms of IBD are Crohn’s disease (CD) 
and Ulcerative Colitis (UC). UC causes inflammation only in the colon and rectum, 
while CD affects the whole GI tract.  In spite of their distinct features, both UC and CD 
are associated with an increased risk of colon cancer, called colitis associated colon 
cancer (CAC) [92, 177, 191]. 
CAC has distinct features from sporadic colon cancer [93]. Generally, CAC 
arises from the flat mucosa, while most sporadic cancer rises from aberrant polyps. 
Genetic mutations occurring during the development of CAC are different from sporadic 
cancer. In sporadic cancer, APC mutation occurs in the early stage, while p53 mutation 
is found in the relatively late stage. In contrast, p53 mutation is found in the early stage 
of CAC, and APC mutation occurs in the late stage. Due to these differences from 
sporadic cancer, transformation from IBD to colon cancer is not fully understood. 
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Because immune cells play a main role in IBD, research focusing on the immune 
systems is required in the CAC model as well.  
To mimic IBD, animal colitis models were developed using inflammatory agents 
[91]. Dextran sodium sulfate (DSS) is a common inflammatory agent used to induce 
colitis in mice [91]. Because it induces superficial chemical injuries, changes of 
lymphocytes are not involved in DSS-induced colitis. Symptoms of DSS treatment 
resemble the symptoms of UC [192]. In contrast, 2, 4, 6-trinitro benzene sulfonic acid 
(TNBS) is a haptenating agent which induces a variety of changes in lymphocytes in the 
lamina propria [90]. TNBS induced colitis elevates type 1 T helper lymphocytes (TH1) 
similar to CD. 
Estradiol (E2) is an active form of the female sex hormone controlling 
development of female sex organs such as the ovary and uterus in the human body [42, 
43]. Epidemiological data have shown the suppressive property of estrogen signaling on 
colon carcinogenesis. The incidence of colon cancer in pre-menopausal women is lower 
than age-matched men, and hormone replacement therapy in post-menopausal women 
lowers the risk of colon cancer [52, 54]. Previous data from our laboratory have shown 
that E2 inhibited formation of aberrant crypt foci (ACF), which are preneoplastic lesions, 
against sporadic colon carcinogenesis by azoxymethane (AOM), and the protective 
effect of E2 is mediated by ERβ and p53 [53, 143].  
Recent articles have demonstrated that E2 influences the immune system [115, 
116]. ERs are expressed on most immune cells, and estrogen signaling regulates the gene 
expression of nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) and 
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interleukin-6 (IL-6), which are major modulators of inflammation [117, 118, 193, 194]. 
Studies with experimental colitis models have demonstrated that E2 reduced the damage 
of the colon via alteration of mast cell numbers and cytokine levels [124, 125, 192]. Still, 
the influence of E2 against inflammation remains debatable because the effect of E2 is 
conflicting; anti- and pro-inflammatory depending on the inflammatory agent. E2 
protected against acute inflammation by TNBS or 2,4-dinitrobenzene sulfonic acid 
(DNBS), while E2 exacerbated the severity of damage with DSS. Epidemiological 
studies have shown that the severity of CD symptoms, but not UC, in pre-menopausal 
women depends on their menstruation cycle. This suggests that E2 has dual effects 
against colonic inflammation [123]. Furthermore, most research on the relationship 
between inflammation and E2 was conducted using male animals. Therefore, an 
experiment with female mice offers an opportunity to clarify the effect of E2 against 
chronic inflammation. Studies have also examined the role of estrogen signaling on CAC 
but the results are debatable [55, 126, 195]. When colon carcinogenesis was induced by 
DSS treatment with the injection of AOM, a colon carcinogen, ACF formation was 
exacerbated or ameliorated by E2 depending on the timing of E2 treatment. Therefore, 
studies are required to clarify the role of E2 on chronic inflammation in the colon and 
CAC. 
The first aim of the present study is to clarify the influence of estrogen signaling 
on chronic inflammation by TNBS. Compared to DSS, the TNBS colitis model has 
shown similar features to CD in which E2 plays a protective role. Though E2 showed a 
protective role in an acute TNBS colitis model, chronic inflammation is a completely 
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different condition, more similar to IBD [125]. The secondary aim of this study is to 
evaluate the effect of estrogen signaling on CAC induced by the co-treatment of AOM 
and TNBS. Genistein (GEN) was utilized in the present study because GEN is a 
representative phytoestrogen isolated from soybeans and known to have anti-
inflammatory activity [128]. Studies from our laboratory and other researchers suggest 
that ERβ mediates the protective role of E2 in both sporadic and inflammation-associated 
colon cancer [55, 196]. Because GEN has a higher binding affinity to ERβ while E2 
preferentially binds to ERα, a comparison of E2 with GEN gives more hints to 
understanding the role of estrogen signaling on chronic inflammation and CAC.  
 
4.2 Materials and methods 
4.2.1 Reagents 
β-Estradiol (E2), 2,4,6-Trinitrobenzenesulfonic acid (TNBS) and azoxymethane 
(AOM) were purchased from Sigma Aldrich. Genistein was provided by Dr. William 
Helferich at the University of Illinois at Urbana-Champaign.  
4.2.2 Animals 
c57BL6 mice were purchased from Charles River Laboratories. Mice were 
housed at the Laboratory Animal Resources and Research facility at Texas A&M 
University. All procedures were performed under protocols approved by the Institutional 
Animal Care and Use Committee at Texas A&M University.  
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4.2.3 Colitis and colitis-associated colon cancer induction  
For chronic inflammation, c57BL6 mice were ovariectomized and either a 20 mg 
cholesterol or 19 mg cholesterol with 1 mg E2 pellet was implanted as described 
previously [53]. Mice were fed a semi-purified phytoestrogen-free diet (AIN-76, Lab 
Supply) or genistein 1000ppm diet post surgery. Mice were allowed food and water ad 
libitum. Two weeks after surgery, mice received 1% TNBS on the skin on their back for 
pre-sensitization.  A week later, TNBS in 50% ethanol was intrarectally injected using a 
flexible plastic gavage tube (Instech Solomon) once a week for 5 weeks. The 
concentration of TNBS continuously increased from 0.5% to 1% to maintain the 
inflammatory response. Two weeks after the last injection of TNBS, mice were 
sacrificed and tissues were collected for analysis. Colons were excised and opened 
longitudinally. One longitudinal half of the colon was fixed with 4% paraformaldehyde 
(PFA; Mallinckrodt Baker, Inc.) and processed for embedding in paraffin.  The other 
half of the colon was frozen in liquid nitrogen for analysis of cytokines.  
For inflammation associated colon carcinogenesis, c57BL6 mice were 
ovariectomized and either a 20 mg cholesterol or 19 mg cholesterol with 1 mg E2 pellet 
was implanted as above. Mice were fed with a semi-purified phytoestrogen-free diet or 
genistein 1000ppm diet at the time of surgery and allowed food and water ad libitum. 
Three weeks after surgery, mice received AOM once a week for 4 weeks at 10 mg/kg 
body weight. 1% TNBS was treated on the skin of their back for presensitization at the 
first injection of AOM.  Mice were intrarectally treated with 2% TNBS in 50% ethanol 
on day 29 and 1.75% TNBS in 50% ethanol on day 43. On day 84, mice were sacrificed, 
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and tissues were collected for analysis. Colons were excised and opened longitudinally.  
1-cm sections from the distal end were fixed in 4% PFA. The remainder of the colon was 
flattened between sheets of filter paper and fixed in 70% ethanol. Ethanol-fixed colons 
were stained with 0.5% methylene blue (Sigma-Aldrich), and aberrant crypt foci (ACF) 
were counted as previously described [197, 198]. 
4.2.4 Colon cytokines  
Colon tissues were snap frozen and homogenized in T-PER Tissue protein 
extraction reagent (Thermo Scientific). Total protein concentration was assessed by DC 
Protein Assay (Bio-Rad). The analysis of cytokine levels was performed using Milliplex 
Mouse Cytokine/Chemokine Magnetic bead panel kit (Millipore) according to the 
manufacturer’s protocol.  Briefly, 150 µg of total protein was added per well to a 96 well 
plate, and 25 µl of 1X magnetic bead mixture and 25 µl assay buffer were added. The 
magnetic beads for IL-6, IL-17, MCP-1, IL-10, granulocyte-macrophage colony-
stimulating factor (GM-CSF), macrophage inflammatory protein 1α (MIP1α), IL-12, 
IFN-γ and TNFα were utilized. The plate was sealed, covered with foil and incubated 
overnight at 4ºC with gentle shaking. The plate was agitated for 1 h with 25 µl of 
detection antibodies and shaken for 30 minutes with 25 µl of Streptavidin-Phycoerythrin 
at room temperature. The beads were then resuspended in 150 µl Luminex Sheath Fluid, 
and the plate was run on a Luminex 200 after agitation for 5 minutes.  
4.2.5 Histological scoring and immunohistochemistry 
Formalin fixed tissues were embedded in paraffin and sectioned at 4 µm. Tissues 
were stained as described previously [55]. Hematoxylin and eosin stained (H&E) tissues 
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were histologically evaluated for the degree of colon damage. Injury and inflammation 
(Score 0-3) were graded by a board certified pathologist (Dr. Brad Weeks) on H&E 
stained colon sections. Immunohistochemistry for 5-bromo-2'-deoxyuridine (BrdU) was 
performed as reported previously with minor modifications [55]. BrdU was injected at 
30 mg/kg body weight 2 h before sacrifice. The activity of endogenous peroxidase was 
quenched using 3% hydrogen peroxide in methanol for 30 min and antigen retrieval was 
achieved by microwaving in 10 mM citrate buffer for 20 min. Slides were incubated 
with anti-BrdU (Roche), the primary antibody, diluted 1:20 at 4ºC overnight in a 
humidified chamber. The primary antibody was left off of a single section in every 3 to 4 
slides to serve as a negative control. Slides were washed and then incubated with the 
secondary antibody, goat anti-mouse-HRP (Abcam), diluted 1:250 for 2 h. Meyer’s 
hematoxylin was used as the counter stain.  Lastly, slides were dehydrated and 
coverslipped. Twenty well oriented crypts were analyzed per mouse and the number of 
positively stained cells and total cells were counted using digital images acquired by 
microscope.  
4.2.6 Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling 
(TUNEL) assay 
The ApopTag Peroxidase in situ Apoptosis Detection Kit (Millipore) was utilized 
for the TUNEL assay according to the manufacturer’s protocol. Tissues were 
deparaffinized, rehydrated and incubated with proteinase K for 3 min at 37ºC at 10μg/ml 
in PBS. Endogenous peroxidase activity was quenched by incubation in 3% hydrogen 
peroxide, and the slides were treated in equilibrium buffer for 1 h at room temperature 
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(RT). Tissues were incubated with terminal deoxynucleotidyl transferase (TDT) enzyme 
in Reaction buffer for 1 h at 37ºC. One section per 3-4 slides was excluded when the 
TDT enzyme was applied as a negative control. Next, a stopwash solution was applied to 
the sections for 10 min and anti-digoxigenin was applied to the slides for 30 min at RT. 
A 0.5% 3,3’-diaminobenzidine (DAB) solution was utilized as the chromagen for 20 
seconds, and hematoxylin was used as the counter-stain. Finally, the slides were 
dehydrated and coverslipped. Twenty well oriented crypts were analyzed per mouse and 
the number of positively stained cells and total cells were counted using digital images 
acquired by microscope.  
4.2.7 RNA isolation and analysis of gene expression 
For RNA analysis, the colon was washed with PBS and scraped with a glass slide 
to collect cells of the mucosal layer at the time of tissue collection. The mucosa was 
immediately frozen in liquid nitrogen and stored at -80ºC. RNA was isolated using the 
Direct-zol™ RNA MiniPrep kit (Zymo Research). One µg cDNA was synthesized using 
the Transcriptor First Strand cDNA Synthesis Kit (Roche) according to the 
manufacturer’s protocol.  Real-time PCR was performed using FastStart Universal 
SYBR Green Master mix (Roche).  The sequence of the PCR primers were as follows: 
ERα (Forwad: GAC CAG ATG GTC AGT GCC TT, Reverse: ACT CGA GAA GGT 
GGA CCT GA), ERβ (Forward: CAG TAA CAA GGG CAT GGA AC, Reverse: GTA 
CAT GTC CCA CTT CTG AC), CCND1 (Forward: GCG TAC CCT GAC ACC AAT 
CTC, Reverse: ACT TGA AGT AAG ATA CGG AGG GC), PCNA (Forward: TTG 
CAC GTA TAT GCC GAG ACC, Reverse: GGT GAA CAG GCT CAT TCA TCT CT), 
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IL-6 (Forward: CTG CAA GAG ACT TCC ATC CAG, Reverse: AGT GGT ATA GAC 
AGG TCT GTT GG), and 18S as an internal control (Forward: TCA AGA ACG AAA 
GTC GGA GGT, Reverse: GGA CAT CTA AGG GCA TCA CAG).  Prepared samples 
were loaded into 384 well reaction plates and run for 45 cycles in a LightCycler®  480 
(Roche): 10 min at 95ºC, 45 cycles of 15 seconds at 95ºC and 30 seconds at 60ºC. 
Samples were run in triplicate. 
4.2.8 Statistical analysis 
Data are expressed throughout as means ± SEM, which was calculated from at 
least 5 mice per group. The statistical significance among the test groups was determined 
by one-way ANOVA. To compare body weights between groups, generalized estimating 
equations and a Wald test were utilized with a main effect for comparison group, a 
natural cubic spline for the time course, and an interaction between the two, based on an 
assumption of an autoregressive correlation structure. For the analysis of ACF, 
generalized regression models assuming a Poisson distribution were carried out and 
ANOVA-like hypotheses were tested. A p-value of less than 0.05 was considered 
significant. All data were analyzed using Graphpad and a data analysis software R with a 
certified statistician, Dr. Alan Dabney.     
 
4.3 Results 
4.3.1 Estradiol suppressed weight gain and elongation of colon length 
Female mice were chosen to examine the effect of estrogen signaling in vivo. 
Their ovaries were removed to control the level of E2 (Fig 4.1A). There were 3 groups in 
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the animal study for chronic inflammation: control group (fed phytoestrogen-free diet 
with cholesterol pellet), E2 group (fed phytoestrogen-free diet with E2 pellet), and GEN 
group (fed GEN diet with cholesterol pellet). TNBS was injected intrarectally in mice to 
mimic chronic inflammation in the colon. The concentration of TNBS increased during 
the experiment, starting at 0.5% and reaching 1% in the end to maintain the 
inflammatory response. All 3 groups of mice had similar average body weight at the 
beginning of the study. TNBS treatment did not induce weight loss due to its low 
concentration, so the control group continuously gained weight (Fig. 4.1B, p < 0.0001). 
However, GEN as well as E2 treatment inhibited weight gain during the whole 
experiment. When comparing body weight between groups, the treatment effect was 
statistically significant (p < 0.0001). 
Because the length and weight of the colon is the primary indicator for colon 
developmental status, both were measured. E2 treatment decreased the length of the 
colon significantly compared to control or GEN treatment (p = 0.02), while also 
elevating the weight of the colon slightly (Fig. 4.2A and 2B, p = 0.05). As a result, the 
ratio of the colon length to weight was decreased in E2 treated mice (p = 0.05), as 
opposed to the acute TNBS study from our laboratory (Fig. 4.2C) [125]. As reported in 
previous data, E2 increased the uterine weight approximately 10 times (p < 0.0001), and 
GEN increased it by 0.01 g compared to control (Fig. 4.2D). 
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Fig. 4.1 Chronic inflammation induced by TNBS in mice A. Experimental 
design.  B. Change of body weight. Values are means (n=17) ± SEM  
 
 
 
Chronic inflammation by TNBS is associated with tissue damage and immune 
cell infiltration [199]. To examine whether E2 protects tissues from TNBS, inflammation 
and injuries were scored on H&E stained tissues (Fig. 4.3). E2 had no effect on the 
severity of inflammation and reduced injury only slightly. In contrast, GEN significantly 
exacerbated inflammation and injuries on the colon (p = 0.007 and p = 0.01).  
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Fig. 4.2 Change of the colon and uterus A. Colon length, B. Colon weight, C. 
the ratio of colon length to weight, D. Uterus weight. Values are means (n =17) ± SEM, 
Bars without a common letter differ; p < 0.05.  
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Fig. 4.3 Inflammation and injuries in the colon H&E stained tissues were 
examined and scored by a board certified pathologist. Values are means (n =17) ± SEM, 
Bars without a common letter differ; p < 0.05. 
 
 
 
4.3.2 E2 and GEN enhanced the expression of genes related to cell 
proliferation 
Estrogen signaling modifies the expression of genes because ERs function as 
transcription factors [43]. To understand the influence of estrogen signaling in the colon 
epithelium, RNA was isolated from scraped mucosa cells inside the colon and RT-PCR 
was performed measuring the expression of genes related to estrogen signaling. E2 
treatment increased the expression of both ERs and GEN enhanced more ERβ 
expression than ERα (Fig. 4.4A-C). These data suggest that activated estrogen signaling 
could modulate ER expression in colonic epithelial cells. Both E2 and GEN treatment 
elevated gene expression of CCND1 and PCNA (Fig. 4.4D and 4E). Though the increase 
of CCND1 and PCNA by E2 and GEN were not significant, these data suggest an 
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increase in cell proliferation is involved in increased expression of genes associated with 
cell cycle progression and cell proliferation. Interestingly, IL-6 expression was 
decreased by E2 and GEN treatment though IL-6 signaling is positively correlated to cell 
proliferation (Fig. 4.4F) [184].  
 
 
 
 
Fig. 4.4 Change of gene expression in the colon epithelial cells A. ERα, B. 
ERβ, C. the ratio of ERβ/ERα, D. CCND1, E. PCNA and F. IL-6 Values are means (n 
=17) ± SEM. Bars without a common letter differ; p < 0.05. 
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4.3.3 E2 increased the level of TH17-related cytokines and decreased the level of 
TH1-related cytokines 
TNBS induced colitis is mediated by effector CD4+ T lymphocytes, TH1 and 
TH17, and a change of related cytokines [199]. To evaluate the change of immune 
responses and cytokines by E2 and GEN, cytokine levels were examined using a 
Milliplex cyto/chemokine kit (Fig 4.5). IL-17 is released from TH17 cells, while IFN-γ 
and TNFα are produced from TH1 cells. IL-10 is an anti-inflammatory cytokine secreted 
from regulatory T cells (Treg), and IL-6, MCP-1, GM-CSF, and MIP1α are released from 
monocytes and macrophages. IL-6, IL-17 and MCP-1 are associated with TH17 cells 
while IL-12, IFN-γ and TNFα are linked to TH1 cells. IL-6, IL-17, and MCP-1 were 
increased by E2, but the changes were not significant (Fig. 4.5A, 5D, 5G). In contrast,  
IL-12 and IFN-γ were decreased significantly in E2 treated mice (Fig 4.5C and 4.5F, p =  
0.005 and p = 0.006). E2 did not change the level of TNFα, IL-10, GM-CSF, or MIP1α 
(Fig. 4.5B, 5E, 5H and 5I). GEN treatment slightly suppressed the level of IL-12 and 
IFN-γ (Fig. 4.5C and 4.5F). Taken together, E2 treatment modulated immune responses 
via an increase of TH17 related cytokines and a decrease of TH1 linked cytokines.  
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Fig. 4.5 Change of cytokines in the colon A. IL-6, B. IL-10, C. IL-12, D. IL-17, 
E. GM-CSF, F. IFN-γ, G. MCP-1, H. MIP1α, and I. TNFα. Values are means (n =17) ± 
SEM, Bars without a common letter differ; p < 0.05. 
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4.3.4 E2 increased cell proliferation and cell numbers of colon epithelial 
To estimate whether E2 altered cell proliferation of the colon epithelial, BrdU 
staining was performed. Twenty complete crypts per mouse were analyzed for 
proliferative cells and whole cell numbers in the crypts. 1.7 cells of BrdU positive cells 
per crypt were found in the bottom area per crypt in the E2 treated group, twice as many 
as found in the control (p < 0.0001). GEN had no effect on the increase of BrdU positive 
cells compared to control (Fig. 4.6A). The increase of BrdU positive cells by E2 elevated 
the percentage of BrdU positive cells (p = 0.0012), demonstrating that E2 treatment 
increased cell proliferation in the colonic epithelial cells (Fig. 4.6B). To estimate 
apoptosis of the colon epithelial cells, the TUNEL assay was performed and 20 complete 
crypts were analyzed per mouse. E2 increased apoptotic cells in the top of the crypts (p = 
0.05) while GEN had no influence on the number of apoptotic cells (Fig. 4.6C). 
However, the percentage of apoptotic cells was not significantly changed by E2 
treatment (Fig 4.6D). Approximately 20% more cells existed in the crypt in the E2 
treated group compared to control or GEN (Fig. 4.6E, p = 0.0018). Taken together, E2 
enhanced both cell proliferation and apoptosis but the effect of E2 predominantly 
increased total cell numbers of the crypt.  
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Fig. 4.6 Change of proliferative and apoptotic cells in the crypts A. Numbers 
of proliferative cells per crypt, B. Percentage of proliferative cells, C. Numbers of 
apoptotic cells per crypt, D. Percentage of apoptotic cells, and E. Total cell numbers per 
crypt. Values are means (n >8) ± SEM, Bars without a common letter differ; p < 0.05. 
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4.3.5 E2 and Gen suppress ACF formation in colitis-associated carcinogenesis  
To evaluate the effect of estrogen signaling on CAC development, we induced 
ACF formation by co-treatment of AOM, a colon specific carcinogen and TNBS in 
female mice (Fig. 4.7A). Three weeks after ovariectomy and implantation of pellets, 
AOM was injected once per week for 4 weeks to induce genetic mutation. At the 2nd and 
4th injection of AOM, TNBS was injected intrarectally to develop CAC by a 
combination of genetic mutation and inflammation. E2 treatment suppressed body weight 
gain compared to control and AOM with TNBS injection induced a slight weight loss 
(Fig. 4.7B). Change in body weight between groups was significant (p < 0.0001). 
However, GEN treatment did not influence body weight until the last injection of AOM 
and TNBS. Though colon length and weight were not changed significantly by any 
treatment, E2 treatment slightly decreased colon length and increased colon weight, 
similar to the study for chronic inflammation (Fig. 4.8A and 4.8B). Uterine weight was 
increased by E2 treatment as expected (Fig. 4.8C, p < 0.0001).  
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Fig. 4.7 Colitis associated colon carcinogenesis by AOM and TNBS A. 
Experimental design, B. Change of body weight. Values are means (n >5) ± SEM  
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Fig. 4.8 Change of the colon and uterus on CAC A. Colon length, B. Colon 
weight, and C. Uterus weight. Values are means (n >5) ± SEM, Bars without a common 
letter differ; p < 0.05. 
 
 
 
Because ACF are premalignant lesions, the number of ACF is considered a 
primary predictor of colon tumor formation [12]. When ACF were counted through 
microscopic observation after staining with 0.5% methylene blue, multiple ACF per 
colon were observed in all three groups (Fig. 4.9A and 9B). The ACF numbers were 
analyzed using Poisson model and Bonferroni adjustment for multiple tests. E2 treatment 
significantly reduced high multiplicity ACF (p = 0.02) as well as total ACF numbers (p 
= 0.0008). GEN slightly decreased total ACF numbers (p = 0.05) and significantly 
decreased high multiplicity ACF (p = 0.015). To examine how ACF formation was 
decreased, cell proliferation and apoptosis were analyzed through BrdU 
immunohistochemistry and the TUNEL assay (Fig. 4.8C and 4.8D). A decrease in cell 
proliferation in the bottom of crypts and an increase of apoptosis in the top of crypts 
were observed, but these were not significantly different across treatments.  
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Fig. 4.9 The suppression of ACF formation by E2 and GEN on CAC A. ACF 
numbers, B. High multiplicity ACF numbers, C. Percentage of proliferative cells, and D. 
Percentage of apoptotic cells. Values are means (n >5) ± SEM, Bars without a common 
letter differ; p < 0.05. 
 
 
 
4.4 Discussion 
It is known that chronic inflammation is associated with increased cancer 
incidence, and specifically, IBD is positively correlated to the risk of colon cancer [84-
86]. The symptoms of Crohn’s Disease (CD), one type of IBD, in women are 
exacerbated when the level of E2 becomes lowest during the menstrual cycle [123]. 
Animal studies have suggested that E2 has a protective effect against CAC as well as 
inflammation [115, 126].  To date, the role of estrogen signaling on chronic 
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inflammation and CAC has not yet been fully explained. In the present study, the 
influence of E2 and GEN on chronic inflammation induced by TNBS and CAC induced 
by AOM and TNBS, was demonstrated.  
Previous studies of acute TNBS treatment have shown that the colon length was 
shortened by TNBS compared to the untreated control [125, 200]. On the other hand, 
previous data from our laboratory suggest that E2 elongated colon length, which is a part 
of its protective response to acute inflammation induced by TNBS. However, E2 
treatment during chronic inflammation did not increase but instead shortened the length 
of the colon. Though the untreated control was not involved in this study, the effect of E2 
on colon length suggested two possible mechanisms: E2 worsened inflammation and 
tissue damage or affected other ways to protect tissues. Interestingly, E2 neither 
increased nor decreased inflammation and injuries, suggesting E2 treatment did not 
exacerbate tissue damage under chronic inflammation.  Instead, E2 increased the mRNA 
expression of CCND1 and PCNA, elevated proliferation and total cells per crypt, and 
had no significant impact on apoptosis. These data indicate that E2 promoted the cell 
proliferation rate in tissues damaged by TNBS. Studies have reported that E2 could 
suppress cell proliferation and increase apoptosis in the colon epithelial cells, and protect 
against sporadic colon carcinogenesis and CAC development [53, 126]. In contrast, a 
study has reported the tumorigenic effect of E2 in CAC [195]. These conflicting data 
suggest that the roles of E2 could differ depending on a variety of factors.  
The major form of ER in the colon is ERβ [47]. In contrast to ERα, ERβ has a 
protective role in tumorigenesis via suppression of cell proliferation. Furthermore, the 
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expression of CCND1 was directly regulated by ERs. ERβ decreased CCND1, while 
ERα increased it using different partners for the transcription complex. Though the ratio 
of ERβ/ERα was not significantly changed, E2 enhanced the mechanism for cell 
proliferation by increasing CCND1 in this study. These data suggest that E2 could induce 
CCND1 expression in spite of highly expressed ERβ, resulting in cell proliferation.  
The immune system plays a main role in chronic inflammation by TNBS similar 
to IBD [89, 90]. Communication between cytokines and roles of immune cells for 
immune responses are complex. Studies have reported that IBD damages colon epithelial 
and effector T cells are activated to fight microbial products invading the colon through 
impaired barrier function. In response to microbial products, myeloid cells, phagocytic 
cells such as monocytes, macrophages and dendritic cells, in the lamina propria release 
cytokines to activate effector T cells [103]. Therefore, cytokines related to effector T 
cells and myeloid cells were estimated in the chronic inflammation study. Myeloid cells 
produce a variety of cytokines including IL-6, MCP-1 and GM-CSF to recruit and 
activate T lymphocytes. Depending on the pathologic condition, the types of cytokines 
released from myeloid cells are different, leading to activation of different types of 
effector T cells. Here, several cytokines released from myeloid cells were examined: IL-
6, MCP-1, GM-CSF, MIP1α, IL-12 and IFN-γ. Among them, IL-6 and MCP-1 were 
increased in E2 treated mice. Combined with increased IL-17 level by E2 treatment, 
elevation of IL-6 and MCP-1 by E2 indicates that E2 treatment enhanced the TH17 
mediated immune response. IL-12 and IFN-γ were decreased in E2 treated mice, 
suggesting that E2 inhibited TH1 activation. In contrast, GM-CSF and MIP1α were not 
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changed by E2, suggesting that E2 modulates specific immune responses in myeloid cells. 
IL-10 is an anti-inflammatory cytokine produced from TReg, which suppresses immune 
responses. E2 has no impact on IL-10, suggesting TReg activation was not changed by E2. 
It has been reported that the immune response induced by TNBS is similar to CD, 
which is associated with TH1 and TH17 [87, 89, 90]. The influence of TH1 and TH17 on 
colitis and CAC has been studied [94, 102]. Though both cells play a critical role in IBD 
and other immune responses, the function of TH1 predominantly focuses on removal of 
damaged cells, while TH17 enhances tissue recovery by cell proliferation [107]. TH1 
cells are positively correlated to removal of dysplastic cells because IFN-γ secreted by 
TH1 cells has anti-proliferative properties in colitis and TH1 cells induce the activation of 
cytotoxic CD8+ T cells. Furthermore, loss of IFN-γ impaired colon tumor formation in 
the CAC model. In contrast, TH17 is known as an inducer of cell proliferation due to IL-
6 and IL-17. IL-6 secreted from macrophages induces activation of TH17 cells, which 
produces IL-17. Increased IL-6 and IL-17 has been found in IBD and colitis-associated 
colon cancer patients and the level of these cytokines is positively correlated with a poor 
prognosis in colon cancer [98, 109]. Previous data from Chapter II has shown that IL-6 
treatment increased cell growth of non-malignant colonocytes, suggesting a tumorigenic 
effect of IL-6 in the colonic epithelial cells. Furthermore, competition between TH1 and 
TH17 has been reported [102]. IL-17 suppresses TH1 cell differentiation, and IFN-γ 
reduces TH17 cell numbers. Therefore, suppression of TH1 by E2 could enhance 
differentiation of TH17 cells, resulting in increased cell proliferation by alteration of the 
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TH1/TH17 ratio. These data suggest that E2 protects the colon via enhanced recovery of 
the colon tissue.  
IL-6 is a major cytokine in chronic inflammation, which is elevated in IBD and 
colon cancer [109]. Studies have reported that intestinal epithelial cells express IL-6 
receptor and IL-6 signaling is activated during colon carcinogenesis via an increase of 
gp130, one component of the transmembrane receptor complex for IL-6 signaling [113, 
201]. These data supported the hypothesis that IL-6 signaling could be activated in 
colonic epithelial cells during colitis and CAC. Interestingly, its expression in colon 
epithelial cells was suppressed slightly by E2 in this study. It is known that estrogen 
signaling decreases IL-6 expression via inhibition of NFκB dimerization, not direct 
binding to the IL-6 promoter. Therefore, E2 treatment tightly modulates cell proliferation 
via suppression of IL-6 expression in the colonic epithelial cells, though E2 increased IL-
6 secretion in the lamina propria.  
In the CAC model, the change in colon length and weight was not significant 
between groups. Because mice were sacrificed 6 weeks after the last injection of TNBS 
and there is no published report that AOM injection altered colon length or weight, the 
effect of TNBS on the colon physiology via colitis could be weak. Still, E2 treated mice 
had slightly shorter but heavier colons than control mice, indicating that E2 shortened the 
colon length against TNBS as observed in the chronic inflammation study.  
Though CAC development has a distinct mechanism compared to sporadic colon 
cancer, E2 treatment reduced ACF formation in the present CAC model, supporting the 
protective effect of E2 against CAC [93]. Surprisingly, no significant difference was 
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found in proliferation or apoptosis in the colon crypts in the CAC experiment. These 
data support the assumption that the role of estrogen signaling is complicated. Estrogen 
signaling enhances apoptosis not cell proliferation in healthy colonic epithelial and it is 
mediated by ERβ, the predominant ER in the colon [75]. E2 treatment elevated apoptosis 
to protect against sporadic colon carcinogenesis by AOM [53]. However, the role of 
estrogen signaling was opposite in the chronic inflammation model. During chronic 
inflammation, E2 treatment induced cell proliferation for recovery of damaged tissues 
via an increase of TH17 and a decrease of TH1. In the CAC model, AOM and TNBS 
were injected together, causing inflammation and genetic mutation at the same time. 
Therefore, the time at which the mice were sacrificed could be a transition time in which 
estrogen signaling moves its focus on apoptosis of dysplastic cells, from cell 
proliferation for tissue recovery because the last TNBS injection was 6 weeks before 
sacrifice. Changes of both cell proliferation and apoptosis were not statistically 
significant, possibly due to dual effects of estrogen signaling.  
GEN is a phytoestrogen that has anti-inflammatory, anti-tumorigenic and pro-
apoptotic properties [64, 75, 128]. GEN has more binding affinity to ERβ than ERα [77]. 
Because the major form of ER in the colon is ERβ, and ERβ mediates protection against 
colon carcinogenesis, GEN as an ERβ agonist was predicted to be a good candidate to 
protect the colon through ERβ against colitis and CAC in this study [47]. However, GEN 
treatment increased inflammation and injury in chronic inflammation and had no effect 
on colon length, though it suppressed body weight gain similar to E2. Though GEN 
elevated CCND1 and PCNA expression, proliferative cells were not changed by GEN. 
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Furthermore, GEN treatment slightly suppressed activation of TH1 without activation of 
TH17, suggesting that removal of damaged cells is active but cell proliferation is limited 
in the colon treated with GEN. Considering the main protective effect of E2 is due to cell 
proliferation to recover damaged tissues, the effect of GEN enhancing apoptosis could 
cause more damage to the colon. More inflammation and injuries by GEN could be due 
to enough TH1 with low TH17. GEN treatment suppressed ACF formation slightly in the 
CAC model. Taken together, GEN could be a good alternative to prevent CAC, but it 
may exacerbate the severity of colitis.  
In conclusion, the present data demonstrate the dual effect of estrogen signaling 
on colitis and CAC. Though estrogen signaling primarily has an apoptotic effect on the 
colonic epithelial cells via ERβ, the effect of estrogen signaling could be pro-
proliferative during colitis without a shift in the expression of ERβ to ERα. During CAC, 
estrogen signaling plays both roles: induction of apoptosis and cell proliferation for 
inhibition of ACF formation. The dual roles of estrogen signaling provide important 
clues to understand the potential mechanism of estrogen signaling against colitis as well 
as CAC, and offers new insights for the protective role of estrogen signaling on colon 
cancer.  
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CHAPTER V 
ESTRADIOL SUPPRESSES COLON CARCINOGENESIS IN SPITE OF LOSS OF 
P53 
 
5.1 Introduction 
Cancer is a prevalent health problem worldwide and accounts for one in four 
deaths in the United States [1]. Though cancers are variable and distinct from one 
another, all cancers are derived from aberrant cell proliferation with the potential for 
invasion into other tissues or organs [6, 202]. Uncontrolled cell proliferation starts with 
genetic changes such as a loss of a chromosome or a genetic mutation. Because cell 
division occurs continuously to maintain human life, the chance of genetic alteration 
exists all the time. When a genetic change occurs in the gene critical to regulation of cell 
proliferation, cells lose the ability to control proliferation and are transformed into tumor 
cells. Still, organisms have protective mechanisms to prevent dysregulated cell 
proliferation. The DNA repair system fixes altered genes via Ataxia-Telangiectasia 
mutated (ATM) and Ataxia-Telangiectasia and Rad-3-related (ATR), reducing the 
chance of error during gene replication by 1 in 2×107 cell divisions [203, 204]. If genetic 
changes cannot be repaired by the DNA repair system, cells induce programmed cell 
death called apoptosis. Apoptosis is the process of controlled cell destruction by 
complex signaling cascades such as caspases [205, 206]. If cells evade these 
mechanisms, they transform into tumor cells and cancer develops.  
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p53 is a tumor suppressor gene known to be a short-lived transcription factor [16, 
207]. Mutation of p53 is found in a variety of cancers, and over 20 million people have 
tumors in which p53 itself or p53 signaling is abrogated [131]. Most p53 mutations are 
found in the DNA binding domain of p53 [16, 208]. Mutated p53 has oncogenic 
properties and can disrupt p53 signaling. p53 is a central mediator of the protective 
mechanisms for controlling cell proliferation including cell cycle arrest, the DNA repair 
system and apoptosis in response to a variety of stresses. When any stress exists, such as 
DNA damage or hyperproliferative signaling, p53 is activated and active p53 modulates 
the expression of genes related to cell cycle progression and apoptosis. Because p53 
signaling alters cell fates, it is tightly regulated by mouse double minute 2 homolog 
(Mdm2). Mdm2 is an E3 ubiquitin ligase that recruits p53 to degradation via 
ubiquitination.  
p53 plays a critical role in colon carcinogenesis, and approximately half of colon 
cancer cases show a p53 mutation [209]. Previous data from our laboratory have 
demonstrated that estrogen signaling also has a protective role in sporadic colon 
carcinogenesis via ERβ [53]. However, studies demonstrating the relationship between 
p53 and estrogen signaling have mostly focused on breast cancer [210, 211]. In these 
studies, p53 suppressed ERα mediated estrogen signaling in breast cancer. ERβ is the 
major form of ER in the colon while ERα is predominant in the breast [47]. Because 
ERβ is linked to apoptosis, while ERα is associated with cell proliferation, the role of 
p53 in estrogen signaling could be different in the colon compared to the breast [211]. A 
previous study from our laboratory demonstrated that E2 increased p53 expression as 
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well as modulated the expression of genes known as targets of p53. These findings 
suggest that p53 is a mediator of estrogen signaling involved in preventing colon 
carcinogenesis [143].  
Because of the critical role of p53 in the cell cycle, DNA repair and apoptosis, 
p53 mutation generates a variety of tumors in a genetically modified mouse model [17]. 
Furthermore, p53 null mice develop tumors at a very early age and die by 10 months of 
age. Therefore, numerous problems accompany utilization of p53 null or knockout mice 
in the study of colon cancer. A previous study from our laboratory was conducted with 
p53 heterozygous (p53+/-) mice to examine the role of p53 in the protective effect of 
estrogen signaling against colon carcinogenesis [144]. More ACF, which are 
premalignant lesions, were found in p53+/- mice treated with azoxymethane (AOM), but 
E2 treatment still had a protective effect in p53
+/- mice treated with AOM. Compared to 
p53+/+ (Wild Type) mice, the protective efficacy of E2 was decreased by approximately 
50%. To conduct experiments with p53 null conditions in the colon, intestinal epithelial 
cell specific p53 knockout mice were developed [136]. These mice are called Tp53ΔIEC 
and exhibit a genetic mutation that causes loss of the exons 2–10 of Tp53 in their IECs 
only. Tp53ΔIEC mice appear healthy and are fertile, indicating that loss of p53 in IECs 
alone is not sufficient for colon cancer. However, when AOM was injected to induce 
colon cancer, these mice developed more tumors via impaired apoptosis and increased 
DNA damage. Therefore, Tp53ΔIEC mice could be a good model to demonstrate the role 
of p53 in estrogen signaling during colon carcinogenesis.  
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The aim of this study was to demonstrate the role of p53 in the protective activity 
of estrogen signaling in the development of sporadic colon cancer. Though the influence 
of p53 on estrogen signaling is partially implied by the experiment with p53+/- mice, it is 
still not clear because p53+/- mice have active p53 signaling. In the present study, we 
utilized Tp53ΔIEC mice injected with AOM, to examine whether p53 plays a pivotal role 
in the protective effect of estrogen signaling. These data will clarify the relationship 
between p53 and estrogen signaling in colon carcinogenesis.  
 
5.2 Materials and methods 
5.2.1 Animals 
Tp53Flox/Flox mice (Background: c57BL6) were purchased from the Jackson 
Laboratory (Strain name: B6.129P2-Trp53tm1brn/J). Villin-CRE mice (Background: 
c57BL6) were obtained from the National Cancer Institute/National Institutes of Health 
(Strain number: 01XE7). Mice were bred in the Laboratory Animal Resources and 
Research facility at Texas A&M University as previously reported [136]. By mating 
Tp53Flox/Flox mice and villin-CRE mice, offspring (F1) of genotypes Tp53Flox/+/Cre and 
Tp53Flox/+ were obtained. By mating two F1 offspring, F2 offspring were produced. 
Among them, Tp53ΔIEC mice (Tp53Flox/Flox/Cre) and Tp53Flox/Flox mice (Tp53Flox/Flox) were 
identified by genotyping. These two mice were mated, and F3 offspring: Tp53ΔIEC mice 
(Tp53Flox/Flox/Cre) and Tp53Flox/Flox mice (Tp53Flox/Flox) were produced and utilized for the 
present experiment. Mice were housed at the Laboratory Animal Resources and 
Research facility at Texas A&M University. All procedures were performed under 
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protocols approved by the Institutional Animal Care and Use Committee at Texas A&M 
University.  
5.2.2 ACF induction  
Tp53Flox/Flox mice and Tp53∆IEC mice were ovariectomized and either a 20 mg 
cholesterol or a 19 mg cholesterol with 1 mg E2 pellet was implanted as described in a 
previous article [53].  After 2 weeks, mice received 6 weekly injections of 10 mg/kg 
AOM. Pellets were replaced 8 weeks after ovariectomy. Seven weeks after the last 
injection of AOM, mice were injected with 5-bromo-2’-deoxyuridine (BrdU). Two h 
later, mice were sacrificed and tissues were collected. Blood was collected by cardiac 
puncture. Colons were excised and opened longitudinally. 1 cm sections from the distal 
end and excised tumors were fixed in 4% paraformaldehyde (Mallinckrodt Baker, Inc.). 
The remainder of the colon was flattened between sheets of filter paper and fixed in 70% 
ethanol. Ethanol-fixed colons were stained with 0.5% methylene blue (Sigma-Aldrich) 
and aberrant crypt foci (ACF) were counted as previously described [198].  
5.2.3 Reagents 
β-Estradiol (E2) and azoxymethane (AOM) were purchased from Sigma Aldrich.  
5.2.4 Statistical analysis 
The data are expressed throughout as the means ± SEM, which was calculated 
from at least 12 mice per group. To compare body weights between groups, generalized 
estimating equations and a Wald test were utilized with a main effect for comparison 
group, a natural cubic spline for the time course, and an interaction between the two, 
based on an assumption of an autoregressive correlation structure. For the analysis of 
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ACF and tumors, generalized regression models assuming a Poisson distribution were 
carried out and ANOVA-like hypotheses were tested. A p-value of less than 0.05 was 
considered significant. All data were analyzed using Graphpad and a data analysis 
software R with a certified statistician, Dr. Alan Dabney.     
 
5.3 Results 
5.3.1 E2 suppressed ACF formation in Tp53ΔIEC as well as Tp53Flox/Flox  
To investigate the effect of E2 on ACF formation, Tp53
∆IEC mice and Tp53Flox/Flox 
mice were divided into two groups: control and E2. The average body weight in all four 
groups of mice began similarly and did not increase significantly during AOM treatment. 
After the last injection of AOM, an increase in body weight was observed (Fig. 5.1B). 
The difference in body weight between the control and E2 group in Tp53
∆IEC mice was 
not significant and only Tp53Flox/Flox mice treated with E2 had a lower body weight 70 
days after starting the experiment compared to the control group in Tp53Flox/Flox mice (p 
= 0.04). As reported in previous data, E2 increased uterine weight approximately 10 
times the weight of control (Fig. 5.1C, p < 0.0001). 
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Fig. 5.1 Induction of sporadic colon cancer in Tp53Flox/Flox and Tp53ΔIEC mice 
A. The experimental design, B. Change of body weight, and C. Uterine weight. Values 
are means (n>11) ± SEM, Bars without a common letter differ; p < 0.05. 
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ACF and tumor numbers were counted using microscopic analysis. Tp53Flox/Flox 
mice had a lower number of ACF than Tp53ΔIEC mice, but the difference of ACF 
numbers was not significant (Fig 5.2A). There was a slight increase in high multiplicity 
ACF in Tp53ΔIEC mice compared to Tp53Flox/Flox mice (Fig. 5.2B). However, tumor 
incidence in Tp53ΔIEC mice was high, while tumors were rarely found in Tp53Flox/Flox 
mice (Fig 5.2C, p < 0.0001). These data demonstrate that loss of p53 in Tp53ΔIEC mice 
promoted ACF formation.  
In Tp53Flox/Flox mice, mice treated with E2 had a slightly lower number of total 
ACF than control mice, while also having a slightly higher number of high multiplicity 
ACF compared to the control, but those changes were not significant. In addition, tumor 
numbers were slightly decreased by E2 treatment compared to control in Tp53
Flox/Flox 
mice.  E2 treatment had a protective effect in Tp53
ΔIEC mice. In Tp53ΔIEC mice, E2 
treatment did not decrease total ACF, but reduced high multiplicity ACF and tumor 
numbers compared to control (Fig. 5.2, p = 0.13 for high multiplicity ACF and p < 
0.0001 for tumors).  
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Fig. 5.2 ACF and tumor formation in Tp53Flox/Flox and Tp53ΔIEC mice A. Numbers 
of ACF, B. Numbers of high multiplicity ACF, C. Numbers of tumors, and D. Numbers 
of ACF and tumors. Values are means (n >12) ± SEM, Bars without a common letter 
differ; p < 0.05. 
 
 
 
5.4 Discussion 
p53 is a tumor suppressor protein functioning as a key mediator that controls cell 
fates [16]. As a transcription factor, p53 modulates gene expression associated with cell 
cycle progression and apoptosis in response to a variety of stress signals. 
Epidemiological and clinical studies have demonstrated the suppressive role of p53 in 
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cancer [131, 135]. Previous studies from our laboratory have shown that the protective 
effect of estrogen signaling in colon cancer involves the p53 pathway in non-malignant 
colonocytes and p53+/- mice [143, 144]. Further experimentation is required to clarify the 
interaction between estrogen signaling and the p53 pathway in colon cancer.  In the 
present study, IEC-specific p53 knockout mice, Tp53ΔIEC mice, were utilized to induce 
colon cancer.  
Previous data from our laboratory show that a partial loss of p53 was not 
sufficient for an increase in ACF in p53+/- mice with an AOM injection [144]. However, 
as previously reported, Tp53ΔIEC mice were more susceptible to AOM induced ACF 
formation compared to Tp53Flox/Flox mice [136]. This was due to p53 loss, resulting in 
more ACF and tumors. These data suggest that the p53 null condition is critical for colon 
carcinogenesis.  
However, E2 treatment did not decrease ACF and tumor formation significantly 
in Tp53Flox/Flox mice. These data are different from previous data from our laboratory, in 
spite of the same background: c57BL6 [53]. These data could be due to the transition 
from ACF to tumors.  
Interestingly, E2 treatment significantly reduced tumor formation in Tp53
ΔIEC 
mice and slightly decreased high multiplicity ACF showing that E2 still has a protective 
effect in colon carcinogenesis in spite of p53 loss. Though activated estrogen signaling 
increased p53 and p53 mediated genes in non-malignant colonocytes, these data suggest 
that p53 is not the only mediator for the suppression of cell proliferation by estrogen 
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signaling [143]. Therefore, further study is required to identify the mediator of estrogen 
signaling against colon carcinogenesis.   
In conclusion, the present data demonstrated that estrogen signaling still has a 
protective effect despite loss of p53. These data suggest that estrogen signaling could 
protect against colon carcinogenesis independent of the p53 pathway, though the p53 
pathway is activated by E2 treatment in colonocytes. Therefore, further investigation of 
potential mechanisms of estrogen signaling during colon cancer progression would give 
more insight into colon carcinogenesis.  
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CHAPTER VI 
SUMMARY AND CONCLUSIONS 
 
Colon cancer develops from complex changes in the colon epithelial layer 
resulting from uncontrolled cell proliferation and a series of genetic mutations [6, 9]. 
Numerous risk factors for colon cancer have been identified, and chronic inflammation 
such as IBD is one of the major predisposing conditions for colon cancer [13, 85]. 
Estrogen signaling has a protective effect on colon carcinogenesis and can modulate the 
adaptive immune system’s role in inflammation [53, 115]. Therefore, studying the role 
of estrogen signaling on colitis and colon carcinogenesis will help clarify the potential 
mechanism of estrogen signaling in colon cancer. In the present studies, the protective 
effect of estrogen signaling has been demonstrated and the protective mechanism of 
estrogenic molecules was investigated in vitro and in vivo on inflammation and colon 
cancer models.  
In the in vitro study, E2 suppressed cell growth of YAMCs via alteration of gene 
expression associated with cell proliferation and apoptosis. However, E2 inhibited the 
effect of IL-6, a pro-inflammatory cytokine, on YAMCs, suggesting that activated 
estrogen signaling by E2 interrupts IL-6 action which decreases apoptosis in non-
malignant colonocytes [104]. The protective effect of E2 led to an opposite outcome in 
chronic inflammation. E2 treatment increased cell proliferation of the colonic epithelial 
cells to promote the recovery of damaged tissues instead of increasing apoptosis. 
However, E2 suppressed the formation of ACF without significant induction of apoptosis 
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or proliferation. Previous data from our laboratory demonstrated that E2 protects against 
sporadic colon carcinogenesis via induced apoptosis [53]. In addition, E2 decreases acute 
inflammation in the colon via modulation of cytokines [125]. Considering previous data, 
the data in the present studies suggest dual effects of E2 on colitis and colitis-associated 
colon carcinogenesis in maintaining the homeostasis of colonic epithelial cells.   
p53 is a major regulator of cell fates, proliferation and apoptosis, and plays an 
important role in colon cancer development [130, 135]. In a previous study with YAMCs, 
the induction of apoptosis by E2 includes the activation of the p53 pathway [143]. In the 
present study, loss of p53 increased ACF formation, but E2 treatment still showed a 
protective property against sporadic colon carcinogenesis. These data suggest that 
estrogen signaling protects the colon independent of the p53 pathway and further study 
is required to identify the potential mechanism of estrogen signaling that enhances 
apoptosis.  
Phytoestrogens are natural compounds that mimic estrogen by interacting with 
ERs [57]. Whether directly binding to ERs or not, they induce the alteration of the 
expression of target genes involved in estrogen signaling. The present studies examined 
the effect of the phytoestrogens, Trig, DIM and GEN, in the colonocytes. Trig and DIM 
have a distinct structure, and they do not directly bind to ERs. Still, Trig suppressed cell 
growth of YAMCs via increased apoptosis, and the effect of Trig was nullified by the 
ER antagonist, ICI. This indicates the estrogenic effect of Trig mediates the changes in 
YAMCs mediated by ERs. DIM influences the expression of genes related to estrogen 
signaling and the effects of DIM include the change of ER transcriptional activity. GEN 
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has a suppressive activity on the cell growth of YAMCs similar to E2, and the induction 
of apoptosis by GEN reduced ACF formation in the CAC model. However, GEN 
enhanced inflammation and injury under conditions of chronic inflammation because it 
has no impact on cell proliferation. These data from studies of phytoestrogens suggest 
that each phytoestrogen induces the activation of estrogen signaling but each has a 
unique mechanism depending on its structure and binding affinity for ERs.  
Overall, the present studies demonstrated the protective role of estrogen signaling 
on colitis and colon cancer in vitro and in vivo. These experiments using different 
experimental models help clarify the dual roles of estrogen signaling in different 
conditions of colon damage and the partially independent mechanism of estrogen 
signaling on the p53 pathway. The comparison of E2 to several phytoestrogens helps 
elucidate the complex mechanism of estrogen signaling. The present studies will provide 
new insight for the role of estrogen signaling in colon cancer.  
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